

CITATION REPORT

List of articles citing

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

DOI: 10.1038/nm1093

Nature Medicine, 2004, 10, 942-9.

Source: <https://exaly.com/paper-pdf/36809418/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2287	Emerging molecular targets for the treatment of pre-eclampsia. 2001 , 5, 395-413		2
2286	Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. 2004 , 64, 8451-5		343
2285	Fatal attraction: tumors beckon regulatory T cells. <i>Nature Medicine</i> , 2004 , 10, 900-1	50.5	107
2284	Deregulation required?. 2004 , 4, 754-754		
2283	CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. 2005 , 28, 120-8		165
2282	Mechanisms of Central and Peripheral T-Cell Tolerance: An Update. 2005 , 32, 384-399		5
2281	Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples. 2005 , 28, 403-11		35
2280	Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. 2005 , 79, 648-54		68
2279	Professional type I interferon-producing cells--a unique subpopulation of dendritic cells. 2005 , 52, 443-62		6
2278	Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. 2005 , 106, 2818-26		134
2277	NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. 2005 , 106, 1392-9		211
2276	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. 2005 , 106, 1008-11		151
2275	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. 2005 , 106, 2018-25		414
2274	Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. 2005 , 106, 3300-7		207
2273	Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. 2005 , 106, 3097-104		212
2272	Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. 2005 , 7, 1056-62		18
2271	Human CD4+ regulatory T cells and activation-induced tolerance. 2005 , 7, 1023-32		13

2270	Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. 2005 , 17, 195-201	88
2269	Human tumor-specific T lymphocytes: does function matter more than number?. 2005 , 17, 320-5	43
2268	The many sounds of T lymphocyte silence. 2005 , 33, 135-47	4
2267	Cell replacement therapy and the evasion of destructive immunity. 2005 , 1, 159-67	8
2266	Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. 2005 , 83, 451-61	232
2265	Immunosuppressive networks in the tumour environment and their therapeutic relevance. 2005 , 5, 263-74	1627
2264	Immunotherapy for pancreatic cancer - science driving clinical progress. 2005 , 5, 459-67	157
2263	NF-kappaB: linking inflammation and immunity to cancer development and progression. 2005 , 5, 749-59	2424
2262	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. 2005 , 19, 2247-53	118
2261	Anti-tumor antibodies in ovarian cancer. 2005 , 54, 55-62	30
2260	Regulatory T cells in ovarian cancer: biology and therapeutic potential. 2005 , 54, 369-77	180
2259	Current immunotherapy of melanoma. 2005 , 5, 111-132	2
2258	Smoldering and polarized inflammation in the initiation and promotion of malignant disease. 2005 , 7, 211-7	1405
2257	Substantial proportions of identical beta-chain T-cell receptor transcripts are present in epithelial ovarian carcinoma tumors. 2005 , 234, 81-101	11
2256	Clinical trials with tumor antigen genetically modified dendritic cells. 2005 , 32, 556-62	8
2255	CD4(+)CD25high regulatory T cells in human pregnancy. 2005 , 65, 111-20	151
2254	Current concepts of tumor-infiltrating lymphocytes in human malignancies. 2005 , 67, 35-50	76
2253	Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. 2005 , 99, 704-13	120

2252	HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. 2005 , 205, 10-8	27
2251	Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. 2005 , 116, 275-81	100
2250	Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. 2005 , 54, 1072-81	90
2249	Regulatory T cells and tumor immunity. 2005 , 54, 1153-61	75
2248	CD4 T cells in tumor immunity. 2005 , 27, 37-48	72
2247	Manipulating dendritic cells to induce regulatory T cells. 2005 , 7, 1033-9	35
2246	Breaking tolerance in cancer immunotherapy: time to ACT. 2005 , 17, 187-94	53
2245	Immunotherapy for melanoma: the good, the bad, and the future. 2005 , 7, 383-92	8
2244	Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. 2005 , 91, 19-28	27
2243	Presence and maturity of dendritic cells in melanoma lymph node metastases. 2005 , 207, 83-90	18
2242	Cancer vaccines: the challenge of developing an ideal tumor killing system. 2005 , 10, 2285-305	13
2241	. 2005 ,	1
2240	. 2005 ,	
2239	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 2005 , 115, 3623-33	788
2238	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. 2005 , 10, 2856-60	49
2237	Therapeutic cancer vaccines: at midway between immunology and pharmacology. 2005 , 5, 611-27	18
2236	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. 2005 , 102, 18538-43	1722
2235	In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. 2005 , 175, 32-6	143

2234	Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. 2005 , 65, 8471-8	84
2233	Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. 2005 , 201, 779-91	363
2232	Chronic stress and susceptibility to skin cancer. 2005 , 97, 1760-7	146
2231	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. 2005 , 202, 907-12	809
2230	Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. 2005 , 11, 1467-73	360
2229	[Immunology--risk management in the body]. 2005 , 130, 1563-5	0
2228	Monoclonal antibody therapy of ovarian cancer. 2005 , 5, 87-96	13
2227	From mice to humans - murine intelligence for human CD8+ T cell vaccine design. 2005 , 5, 263-71	9
2226	Targets in allergy-directed immunotherapy. 2005 , 9, 217-24	5
2225	CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. 2005 , 172, 1434-9	54
2224	Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. 2005 , 175, 1483-90	466
2223	Interleukin-10 and the immune response against cancer: a counterpoint. 2005 , 78, 1043-51	282
2222	Phenotypic and functional differences between human CD4+CD25+ and type 1 regulatory T cells. 2005 , 293, 303-26	62
2221	Strategies of antigen-specific T-cell-based immunotherapy for cancer. 2005 , 20, 491-501	9
2220	Global natural regulatory T cell depletion in active systemic lupus erythematosus. 2005 , 175, 8392-400	368
2219	Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells. 2005 , 174, 6161-8	88
2218	Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. 2005 , 65, 2947-55	31
2217	Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. 2005 , 65, 8479-86	62

2216	The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. 2005 , 11, 8326-31	422
2215	Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. 2005 , 201, 1037-44	326
2214	DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. 2005 , 102, 10846-51	40
2213	Regulatory T cells for immunotherapy of autoimmune diseases: from the bench to the bedside. 2005 , 15, 1595-1616	3
2212	Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. 2005 , 65, 9547-54	60
2211	The therapeutic implications of intratumoral regulatory T cells. 2005 , 11, 8226-9	36
2210	Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. 2005 , 65, 2457-64	500
2209	CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. 2005 , 16, 1360-70	151
2208	Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. 2005 , 78, 14-26	183
2207	Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. 2005 , 65, 5020-6	312
2206	Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. 2005 , 202, 1387-97	232
2205	Human natural killer cells: A comprehensive review. 2005 , 27, 5	6
2204	T regulatory cell depletion can boost DC-based vaccines. 2005 , 4, 628-630	4
2203	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. 2005 , 202, 1075-85	687
2202	Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. 2005 , 4, 1645-52	26
2201	The potential of exosomes in immunotherapy. 2005 , 5, 737-47	40
2200	Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. 2005 , 102, 419-24	606
2199	Immunotherapy for gynaecological malignancies. 2005 , 5, 1193-210	30

2198	Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. 2005 , 202, 919-29	592
2197	Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. 2005 , 309, 1380-4	639
2196	Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. 2005 , 26, 111-7	346
2195	Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. 2005 , 26, 260-7	101
2194	Homing to suppress: address codes for Treg migration. 2005 , 26, 632-6	150
2193	Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. 2005 , 66, 884-91	15
2192	The potential of exosomes in immunotherapy of cancer. 2005 , 35, 111-5	36
2191	Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. 2005 , 35, 149-52	78
2190	Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. 2005 , 117, 144-51	20
2189	The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. 2005 , 23, 2374-8	44
2188	Ovarian cancer, the coagulation pathway, and inflammation. 2005 , 3, 25	90
2187	Immunologic aspect of ovarian cancer and p53 as tumor antigen. 2005 , 3, 34	28
2186	Notch: a unique therapeutic target for immunomodulation. 2005 , 9, 395-410	10
2185	Helicobacter pylori and MALT lymphoma. 2005 , 128, 1579-605	131
2184	Regulatory T cells in transplantation tolerance. 2005 , 293, 249-64	7
2183	A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. 2005 , 7, 1112-22	49
2182	[Phenotypic and functional analysis of T lymphocytes in cancer patients]. 2005 , 25, 211-9	
2181	CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential. 2005 ,	

2180	Role of regulatory T cells in experimental arthritis and implications for clinical use. 2005 , 7, 118-20	14
2179	In Vivo Models of Inflammation. 2006 ,	2
2178	Checkpoint blockade in cancer immunotherapy. 2006 , 90, 297-339	414
2177	The human T cell response to melanoma antigens. 2006 , 92, 187-224	49
2176	Cancer Drug Resistance. 2006 ,	17
2175	Innate immune recognition and suppression of tumors. 2006 , 95, 293-322	50
2174	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. 2006 , 6, 1769-85	18
2173	Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. 2006 , 12, 3355-60	116
2172	Regulatory T cells in cancer. 2006 , 108, 804-11	563
2171	Mechanisms of immune evasion by tumors. 2006 , 90, 51-81	497
2170	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. 2006 , 55, 1432-42	73
2169	Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. 2006 , 3, 668-81	258
2168	Immune cells in colorectal cancer. 2006 , 354, 1531-2; author reply 1531-2	3
2167	In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. 2006 , 4, 52	93
2166	Regulatory T-cell compartmentalization and trafficking. 2006 , 108, 426-31	255
2165	Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. 2006 , 90, 1-50	568
2164	Harnessing the regulatory feedback to T cells to enhance antitumor immune responses. 2006 , 3, 31-34	
2163	Regulation of T cell responses in the developing human fetus. 2006 , 176, 5741-8	191

2162	The tumour microenvironment and implications for cancer immunotherapy. 2006 , 6, 671-84	31
2161	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. 2006 , 24, 5373-80	841
2160	Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. 2006 , 35, 251-77	61
2159	Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. 2006 , 35, 359-94	13
2158	Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. 2006 , 12, 1859-67	97
2157	Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. 2006 , 343, 684-91	62
2156	Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. 2006 , 42, 717-27	1106
2155	Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. 2006 , 247, 4-21	139
2154	Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. 2006 , 45, 246-53	191
2153	Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. 2006 , 45, 254-62	139
2152	T cell infiltration and prognosis in HCC patients. 2006 , 45, 178-81	21
2151	Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. 2006 , 67, 1-12	139
2150	Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. 2006 , 211, 651-61	18
2149	Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. 2006 , 25, 129-41	388
2148	The kiss of death: interrupted by NK-cell close encounters of another kind. 2006 , 27, 161-4	23
2147	Regulatory T cells and Toll-like receptors in tumor immunity. 2006 , 18, 136-42	50
2146	Regulatory T cells in transplantation. 2006 , 18, 111-9	66
2145	Regulatory T cell maintenance of dominant tolerance: induction of tissue self-defense?. 2006 , 17, 7-10	14

2144	Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity. 2006 , 1, 25-32	2
2143	Recent advances in the use of antigen-specific T cells for the treatment of cancer. 2006 , 1, 333-342	2
2142	Future directions for vaccine-based therapies. 2006 , 24, 448-55	3
2141	Basic overview of current immunotherapy approaches in urologic malignancy. 2006 , 24, 413-8	6
2140	Dendritic Cell Manipulation with Biological and Pharmacological Agents to Induce Regulatory T Cells. 545-567	
2139	CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. 2006 , 1, e129	166
2138	Genomics and Functional Differences of Dendritic Cell Subsets. 2006 , 209-247	
2137	Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating tumor immunity, autoimmunity and alloreactive immunity (III). 2006 , 3, 309-16	36
2136	Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. 2006 , 11, 1360-70	50
2135	Immunotherapy as part of a multidisciplinary approach to melanoma treatment. 2006 , 11, 1-14	17
2134	Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. 2006 , 108, 3371-8	137
2133	Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. 2006 , 108, 4260-7	322
2132	Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. 2006 , 107, 381-8	30
2131	Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. 2006 , 107, 628-36	245
2130	Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. 2006 , 107, 3639-46	356
2129	In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. 2006 , 107, 3940-9	243
2128	A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. 2006 , 107, 3251-7	19
2127	Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. 2006 , 108, 390-9	408

2126	Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. 2006 , 108, 2280-9	176
2125	High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. 2006 , 108, 2957-64	404
2124	Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. 2006 , 15, 1315	0
2123	Central and Peripheral Tolerance. 2006 , 63-84	1
2122	Manipulating T regulatory cells in cancer immunotherapy. 2006 , 1, 589-597	3
2121	Targeting tumor-related immunosuppression for cancer immunotherapy. 2006 , 6, 233-7	57
2120	Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. 2006 , 16, 141	13
2119	Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. 2006 , 29, 208-14	61
2118	Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. 2006 , 29, 336-49	39
2117	Immune suppression in the tumor microenvironment. 2006 , 29, 233-40	201
2116	Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. 2006 , 29, 416-24	96
2115	IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. 2006 , 29, 10-20	35
2114	The Tumor Microenvironment. 2006 , 285-301	
2113	CD8+ T-cell memory in tumor immunology and immunotherapy. 2006 , 211, 214-24	369
2112	Infectious tolerance and the long-term acceptance of transplanted tissue. 2006 , 212, 301-13	139
2111	The role of regulatory T cells in alloantigen tolerance. 2006 , 212, 330-43	69
2110	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. 2006 , 212, 28-50	966
2109	CD4+CD25+ regulatory T cells in health and disease. 2006 , 33, 519-24	47

2108	Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. 2006 , 84, 303-17	90
2107	Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. 2006 , 213, 195-212	71
2106	TGF-beta: a mobile purveyor of immune privilege. 2006 , 213, 213-27	184
2105	Immune resistance orchestrated by the tumor microenvironment. 2006 , 213, 131-45	361
2104	The tumor-draining lymph node as an immune-privileged site. 2006 , 213, 146-58	190
2103	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. 2006 , 214, 229-38	204
2102	The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. 2006 , 28, 382-90	23
2101	Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. 2006 , 97, 920-7	10
2100	CCR4 as a novel molecular target for immunotherapy of cancer. 2006 , 97, 1139-46	185
2099	Review article: immune suppression and colorectal cancer. 2006 , 24, 1163-77	69
2098	Regulatory T cells in human disease and their potential for therapeutic manipulation. 2006 , 118, 1-9	101
2097	Paradoxical roles of the immune system during cancer development. 2006 , 6, 24-37	1682
2096	Vaccines for tumour prevention. 2006 , 6, 204-16	256
2095	Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. 2006 , 6, 613-25	219
2094	Regulatory T cells, tumour immunity and immunotherapy. 2006 , 6, 295-307	1581
2093	Adoptive immunotherapy for cancer: building on success. 2006 , 6, 383-93	724
2092	Cancer despite immunosurveillance: immunoselection and immunosubversion. 2006 , 6, 715-27	946
2091	Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. 2006 , 94, 1478-84	27

2090	The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. 2006 , 95, 1202-11	34
2089	Tumor-infiltrating T lymphocytes: friends or foes?. 2006 , 86, 231-45	218
2088	Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sjögren syndrome from other cutaneous T-cell lymphomas. 2006 , 20, 1123-9	80
2087	Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. 2006 , 102, 229-36	51
2086	The role of stroma in immune recognition and destruction of well-established solid tumors. 2006 , 18, 226-31	103
2085	Immune regulation in tumor-bearing hosts. 2006 , 18, 214-9	44
2084	Le traitement du lupus érythémateux systémique en 2006. 2006 , 73, 977-984	
2083	Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. 2006 , 13, 1252-8	106
2082	Effective cancer therapy through immunomodulation. 2006 , 57, 65-81	68
2081	The chemokine network: a target in cancer biology?. 2006 , 58, 962-74	59
2080	Regulating the immune response to tumours. 2006 , 58, 948-61	49
2079	Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. 2006 , 98, 17-29	40
2078	Regulatory T cells: present facts and future hopes. 2006 , 195, 113-24	21
2077	Immunotherapie in der gynäkologischen Onkologie. 2006 , 39, 158-164	
2076	Dynamic control of lymphocyte trafficking by fever-range thermal stress. 2006 , 55, 299-311	29
2075	Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. 2006 , 55, 588-97	20
2074	CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. 2006 , 55, 1064-71	237
2073	Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. 2006 , 55, 1185-97	113

2072	Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. 2006 , 55, 151-9	56
2071	Adoptive T cell therapy of solid cancers. 2006 , 55, 96-103	27
2070	Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. 2006 , 55, 1320-9	35
2069	The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. 2007 , 56, 70-80	23
2068	Epigenetic regulation of immune escape genes in cancer. 2006 , 55, 1159-84	97
2067	Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. 2006 , 55, 1443-50	18
2066	Immunotherapy of renal cell carcinoma. 2007 , 56, 117-28	49
2065	CD4 regulatory T cells in human cancer pathogenesis. 2007 , 56, 271-85	87
2064	Total colectomy improves altered distribution of regulatory T cells in patients with ulcerative colitis. 2006 , 30, 590-7	5
2063	Regulatory T-cells in the control of immunological diseases. 2006 , 85, 747-58	10
2062	Regulatory T cells in experimental autoimmune disease. 2006 , 28, 3-16	56
2061	Regulatory T cells and innate immune regulation in tumor immunity. 2006 , 28, 17-23	39
2060	Regulatory T cells: magic bullets for immunotherapy?. 2006 , 54, 33-43	9
2059	Induction and maintenance of self tolerance: the role of CD4+CD25+ regulatory T cells. 2006 , 54, 307-21	8
2058	Control of immune responses by immunoregulatory T cells. 2006 , 54, 381-91	8
2057	Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. 2006 , 63, 449-68	190
2056	T regulatory cells and migration. 2006 , 6, 1518-23	33
2055	Prospects for exosomes in immunotherapy of cancer. 2006 , 10, 376-88	125

2054	Migration and function of FoxP3+ regulatory T cells in the hematolymphoid system. 2006 , 34, 1033-40	48
2053	Treatment of systemic lupus erythematosus in 2006. 2006 , 73, 591-8	16
2052	Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. 2006 , 121, 358-68	82
2051	Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. 2006 , 49, 59-70	34
2050	TGF-beta in cancer and as a therapeutic target. 2006 , 72, 523-9	57
2049	Vaccines in renal cell carcinoma. 2006 , 33, 614-24	16
2048	Escape from immune- and nonimmune-mediated tumor surveillance. 2006 , 16, 16-31	46
2047	Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. 2006 , 16, 3-15	336
2046	Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. 2006 , 16, 73-9	53
2045	Regulatory T cells: how do they find their space in the immunological arena?. 2006 , 16, 91-7	19
2044	Regulatory cells and human cancer. 2006 , 16, 98-105	69
2043	Functional control of regulatory T cells and cancer immunotherapy. 2006 , 16, 106-14	40
2042	Regulatory T cells in immune surveillance and treatment of cancer. 2006 , 16, 115-23	193
2041	The role of the NKG2D receptor for tumor immunity. 2006 , 16, 333-43	106
2040	Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment. 2006 , 5 Suppl 1, S7-S18	1
2039	Delayed functional maturation of natural regulatory T cells in the medulla of postnatal thymus: role of TSLP. 2006 , 7, 6	48
2038	FOXP3+ regulatory T cells: Current controversies and future perspectives. 2006 , 36, 2832-6	110
2037	Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. 2006 , 106, 2158-64	45

2036	HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. 2006 , 118, 2657-64	72
2035	Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers. 2006 , 2, 379-89	6
2034	Improving T cell therapy for cancer. 2006 , 6, 215-29	19
2033	Biomarkers for the development of cancer vaccines: current status. 2006 , 10, 337-43	14
2032	Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. 2006 , 27, 1086-95	129
2031	Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 2006 , 12, 4294-305	132
2030	T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. 2006 , 11, 384-92	73
2029	Gene Expression Profiling of Epithelial Ovarian Cancer. 2006 , 7, 115-135	3
2028	Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy. 2006 , 9, 420-5	6
2027	Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. 2006 , 176, 6631-9	54
2026	CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. 2006 , 203, 2451-60	184
2025	Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. 2006 , 35, 327-57	32
2024	Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer. 2006 , 2, 261-272	5
2023	The inflammatory tumor microenvironment and its impact on cancer development. 2006 , 13, 118-137	161
2022	Autologous tumor rejection in humans: trimming the myths. 2006 , 35, 437-58	6
2021	Combinational FLT3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. 2006 , 66, 4895-903	26
2020	Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. 2006 , 177, 40-4	221
2019	CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. 2006 , 177, 7398-405	322

2018	Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. 2006 , 12, 4794-803	90
2017	Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. 2006 , 24, 1169-77	301
2016	Modulation of immune response by B7 family molecules in tumor microenvironments. 2006 , 35, 395-418	11
2015	Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. 2006 , 66, 6826-33	45
2014	CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. 2006 , 176, 1582-7	323
2013	Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro. 2006 , 176, 984-90	36
2012	The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. 2006 , 66, 8258-65	55
2011	CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. 2006 , 176, 1750-8	91
2010	Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. 2006 , 24, 5052-9	192
2009	Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. 2006 , 12, 5423-34	586
2008	Regulatory T cells and toll-like receptors in cancer therapy. 2006 , 66, 4987-90	34
2007	Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. 2006 , 66, 7301-9	87
2006	An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. 2006 , 18, 425-34	37
2005	CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. 2006 , 66, 6807-15	264
2004	Chemokines, chemokine receptors, and cancer metastasis. 2006 , 79, 639-51	240
2003	NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic Ovarian Carcinoma. 2006 , 125, 451-458	122
2002	Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. 2006 , 66, 4488-95	213
2001	Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. 2006 , 66, 5716-22	243

2000	Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. 2006 , 66, 10145-52	139
1999	Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. 2006 , 12, 465-72	441
1998	Studying human regulatory T cells in vivo. 2006 , 12, 5265-7	6
1997	Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. 2006 , 103, 1041-6	122
1996	Roadmap to a better therapeutic tumor vaccine. 2006 , 25, 415-43	28
1995	Dendritic cell derived-exosomes: biology and clinical implementations. 2006 , 80, 471-8	103
1994	CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. 2006 , 177, 8191-201	28
1993	Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. 2006 , 177, 5811-8	99
1992	Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. 2006 , 79, 652-62	51
1991	Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. 2006 , 177, 896-904	328
1990	Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. 2006 , 177, 6527-39	108
1989	IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. 2006 , 177, 84-91	111
1988	Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. 2006 , 176, 6340-6	50
1987	Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. 2006 , 66, 4904-12	179
1986	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. 2006 , 203, 871-81	548
1985	The Link Between Inflammation and Cancer. 2006 ,	5
1984	The role of immune cells in the tumor microenvironment. 2006 , 130, 103-24	74
1983	The immune paradox of sarcoidosis and regulatory T cells. 2006 , 203, 359-70	317

1982	Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. 2006 , 66, 3294-302	430
1981	Reply: Controversies on autoimmunity and prognosis in cancer. 2006 , 95, 764-765	1
1980	Vaccination: role in metastatic melanoma. 2006 , 6, 1305-18	21
1979	Interferon beta adenoviral gene therapy in a patient with ovarian cancer. 2006 , 3, 633-9	25
1978	The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. 2006 , 8, 261-79	408
1977	Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. 2006 , 177, 739-47	347
1976	Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. 2006 , 12, 2326s-2330s	76
1975	T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. 2006 , 24, 4254-61	60
1974	Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. 2006 , 66, 11447-54	15
1973	Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. 2006 , 176, 2722-9	174
1972	New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. 2006 , 177, 1670-8	149
1971	Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. 2006 , 103, 9964-9	118
1970	Clinical results of vaccine therapy for cancer: learning from history for improving the future. 2006 , 95, 147-202	38
1969	Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. 2007 , 178, 6730-3	340
1968	Recent advances and current challenges in tumor immunology and immunotherapy. 2007 , 15, 1065-71	27
1967	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. 2007 , 104, 3360-5	1081
1966	Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. 2007 , 178, 2883-92	368
1965	Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. 2007 , 179, 7593-604	101

1964	Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. 2007 , 25, 2586-93	836
1963	Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. 2007 , 178, 7432-41	68
1962	Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. 2007 , 178, 3400-8	7
1961	CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. 2007 , 179, 1996-2004	30
1960	Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. 2007 , 178, 2787-93	35
1959	Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. 2007 , 179, 1532-41	32
1958	Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. 2007 , 179, 4969-78	58
1957	Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 2007 , 179, 2860-9	61
1956	Maternal acceptance of the fetus: true human tolerance. 2007 , 178, 3345-51	186
1955	Immunotherapy of melanoma: a critical review of current concepts and future strategies. 2007 , 7, 345-58	41
1954	CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. 2007 , 178, 5595-605	137
1953	CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. 2007 , 13, 7172-80	18
1952	Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. 2007 , 178, 4089-96	32
1951	A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. 2007 , 13, 4345-54	345
1950	CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. 2007 , 13, 2714-21	87
1949	Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. 2007 , 104, 20884-9	147
1948	Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses. 2007 , 179, 2731-40	37
1947	Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. 2007 , 104, 3390-5	158

1946	Enhanced antitumor responses elicited by combinatorial protein transfer of chemotactic and costimulatory molecules. 2007 , 178, 3301-6	16
1945	Response to Comment on Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells 2007 , 178, 4706-4706	
1944	FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. 2007 , 178, 301-11	103
1943	Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. 2007 , 96, 617-22	108
1942	DNA vaccines for cervical cancer: from bench to bedside. 2007 , 39, 679-89	57
1941	Specific recruitment of CD4+CD25++ regulatory T cells into the allograft in heart transplant recipients. 2007 , 292, H2425-31	12
1940	Epigenetic control of the foxp3 locus in regulatory T cells. 2007 , 5, e38	925
1939	Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. 2007 , 13, 2075-81	168
1938	Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. 2007 , 99, 1188-99	120
1937	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. 2007 , 292, C987-95	251
1936	Regulatory T cells and human disease. 2007 , 2007, 89195	110
1935	Role of monoclonal antibodies in tumor-specific immunity. 2007 , 7, 331-43	8
1934	Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. 2007 , 82, 576-84	35
1933	Regulatory T lymphocytes: pivotal components of the host antitumor response. 2007 , 25, 2506-8	38
1932	Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis. 2007 , 82, 1-15	63
1931	Reversal of tumor-mediated immunosuppression. 2007 , 13, 727s-732s	79
1930	Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. 2007 , 178, 4051-61	70
1929	Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. 2007 , 13, 2961-9	109

1928	Costimulation, coinhibition and cancer. 2007 , 7, 15-30	79
1927	Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. 2007 , 7, 109-20	17
1926	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. 2007 , 83, 819-25	88
1925	CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. 2007 , 104, 19446-51	607
1924	Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. 2007 , 67, 7487-94	129
1923	Clinical features, prognosis and treatment of follicular lymphoma. 2007 , 2007, 216-25	48
1922	Immunologic markers of cancer progression and prognosis. 2007 , 1, 439-50	
1921	Vitamin D receptor agonists as anti-inflammatory agents. 2007 , 3, 477-89	13
1920	FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells. 2007 , 282, 15973-80	39
1919	Regulatory T cells--the renaissance of the suppressor T cells. 2007 , 39, 322-34	19
1918	Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. 2007 , 13, 1883-91	32
1917	Ovarian cancer vaccine trials and tribulations. 2007 , 7, 103-12	
1916	Chemokines, chemokine receptors and CD4+CD25+ regulatory T cells. 2007 , 3, 343-9	3
1915	Clinical utilization of chemokines to combat cancer: the double-edged sword. 2007 , 6, 267-83	38
1914	RA8, a human anti-CD25 antibody against human Treg cells. 2007 , 26, 119-30	2
1913	Genetic modification of T cells for immunotherapy. 2007 , 7, 1167-82	7
1912	Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. 2007 , 28, 2614-23	55
1911	Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. 2007 , 179, 4919-28	148

1910	Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. 2007 , 178, 4891-900	76
1909	Transforming growth factor-beta and the immune response to malignant disease. 2007 , 13, 6247-51	118
1908	Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. 2007 , 13, 1503-10	61
1907	Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. 2007 , 13, 2100-8	70
1906	Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. 2007 , 67, 371-80	127
1905	Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. 2007 , 13, 6494-500	51
1904	Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. 2007 , 67, 1832-41	69
1903	The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. 2007 , 13, 6301-11	216
1902	T-cell distribution and adhesion receptor expression in metastatic melanoma. 2007 , 13, 2549-56	59
1901	High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. 2007 , 67, 354-61	304
1900	Regulatory T cells and toll-like receptors: regulating the regulators. 2007 , 66 Suppl 3, iii91-5	39
1899	Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system. 2007 , 13, 1353-5	18
1898	Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. 2007 , 179, 7365-75	96
1897	1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. 2007 , 178, 145-53	264
1896	Intestinal lamina propria retaining CD4+CD25+ regulatory T cells is a suppressive site of intestinal inflammation. 2007 , 178, 4937-46	88
1895	Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. 2007 , 179, 2851-9	58
1894	How regulatory CD25+CD4+ T cells impinge on tumor immunobiology: the differential response of tumors to therapies. 2007 , 179, 5659-68	28
1893	Breast Cancer. 2007 ,	

1892	Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. 2007 , 178, 2155-62	183
1891	Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. 2007 , 67, 6017-21	108
1890	Immunotherapy of Cancer. 2007 , 211-235	1
1889	FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. 2007 , 13, 902-11	334
1888	CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. 2007 , 13, 6947-58	276
1887	CCR7 mediates the migration of Foxp3+ regulatory T cells to the paracortical areas of peripheral lymph nodes through high endothelial venules. 2007 , 82, 1230-8	37
1886	The cross-talk between dendritic and regulatory T cells: good or evil?. 2007 , 82, 781-94	63
1885	IPEX as a result of mutations in FOXP3. 2007 , 2007, 89017	122
1884	Cellular and molecular mechanisms of tumor-induced T-cell tolerance. 2007 , 7, 41-53	26
1883	Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. 2007 , 7, 3-14	31
1882	G protein-coupled receptor 83 is dispensable for the development and function of regulatory T cells. 2007 , 27, 8065-72	19
1881	In Reply. 2007 , 25, 2630-2632	1
1880	Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. 2007 , 25, 869-75	225
1879	Immunologic approaches to ovarian cancer treatment. 2007 , 25, 2884-93	39
1878	Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. 2007 , 67, 227-36	126
1877	Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. 2007 , 67, 1291-8	46
1876	Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. 2007 , 67, 5929-39	79
1875	Dynamics of the immune reaction to pancreatic cancer from inception to invasion. 2007 , 67, 9518-27	668

1874	Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. 2007 , 67, 8900-5	254
1873	Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. 2007 , 13, 4538-46	76
1872	In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. 2007 , 104, 12457-61	93
1871	CCR4-dependent regulatory T cell function in inflammatory bowel disease. 2007 , 204, 1327-34	100
1870	Targets, trials, and travails in pancreas cancer. 2007 , 5, 1042-53	10
1869	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 2007 , 109, 2871-7	293
1868	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. 2007 , 110, 2537-44	151
1867	PAR4 antagonists in inflammation. 2007 , 110, 3091-3092	1
1866	C/EBP β 30 SUMO wrestles C/EBP β 42. 2007 , 110, 3089-3089	
1865	Immune Stimulatory Features of Classical Chemotherapy. 2007 , 235-256	3
1864	Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. 2007 , 30, 438-47	56
1863	Exploiting regulatory T-cell populations for the immunotherapy of cancer. 2007 , 30, 591-5	15
1862	Regulation and privilege in transplantation. 2007 , 12, 340-344	1
1861	The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. 2007 , 83, 341-6	39
1860	Emerging approaches in hepatocellular carcinoma. 2007 , 41, 839-54	15
1859	IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. 2007 , 30, 294-302	38
1858	Comment on "Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells". 2007 , 178, 4705-6; author reply 4706	5
1857	Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. 2007 , 30, 16-28	137

1856	Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment. 2007 , 70, 36-41	4
1855	Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. 2007 , 25, 6604-12	31
1854	Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. 2007 , 116, 69-78	111
1853	Tumor promotion by tumor-associated macrophages. 2007 , 604, 67-86	69
1852	The essential role of chemokines in the selective regulation of lymphocyte homing. 2007 , 18, 33-43	44
1851	Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. 2007 , 253, 144-53	44
1850	Role of chemokines in tumor growth. 2007 , 256, 137-65	444
1849	Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. 2007 , 78, 1083-93	112
1848	A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. 2007 , 67, 7477-86	169
1847	Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. 2007 , 141, 72-7	56
1846	Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. 2007 , 27, 334-48	307
1845	Intravenous administration of MIP-1alpha with intra-tumor injection of P. acnes shows potent anti-tumor effect. 2007 , 7, 845-57	6
1844	Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. 2007 , 44, 3453-61	37
1843	Natural regulatory T cells: mechanisms of suppression. 2007 , 13, 108-16	547
1842	Regulatory T cells: potential target in anticancer immunotherapy. 2007 , 46, 215-21	10
1841	Immunosuppressive strategies that are mediated by tumor cells. 2007 , 25, 267-96	1260
1840	CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. 2007 , 23, 438-50	108
1839	Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. 2007 , 9, 212	475

1838	General Principles of Tumor Immunotherapy. 2007,	2
1837	Novel agents in ovarian cancer. 2007, 16, 1227-39	9
1836	Tissue vaccines for cancer. 2007, 6, 925-37	5
1835	Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. 2007, 178, 320-9	280
1834	Treg cells, cancer vaccines: timing is everything. 2007, 110, 3090-3091	78
1833	Transforming growth factor-beta and the immune response: implications for anticancer therapy. 2007, 13, 5262-70	347
1832	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. 2007, 110, 3192-201	164
1831	Review: cancer immunotherapy by exosome-based vaccines. 2007, 22, 692-703	48
1830	Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. 2007, 7, 1473-86	27
1829	Regulatory T cells (Treg) and HIV/AIDS: summary of the September 7-8, 2006 workshop. 2007, 23, 945-52	22
1828	Biologic predictors in follicular lymphoma: importance of markers of immune response. 2007, 48, 2403-11	40
1827	Targeting tumour-associated macrophages. 2007, 11, 1219-29	52
1826	Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. 2007, 67, 8344-50	263
1825	Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. 2007, 179, 1423-6	143
1824	Immune-Mediated Diseases. 2007,	4
1823	Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies. 2007, 36, 629-48	17
1822	Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. 2007, 177, 353-8	78
1821	Tumor microenvironment and immune escape. 2007, 16, 755-74, viii	75

1820	Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. 2007 , 132, 2328-39	602
1819	T-cell responses to allergens. 2007 , 119, 280-94; quiz 295-6	104
1818	Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. 2007 , 257-275	
1817	The Local Tumor Microenvironment. 2007 , 145-167	2
1816	T-Regulatory Cell Manipulation in Tumor Immunotherapy. 2007 , 189-204	
1815	Intratumor Generation of Vigorous Antitumor Immune Responses. 2007 , 229-242	
1814	Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy. 2007 , 269-289	
1813	Immune prognostic factors in ovarian cancer: lessons from translational research. 2007 , 23, 445-52	4
1812	Regulatory T cells in Tumor Immunity: Role of Toll-Like Receptors. 2007 , 277-287	1
1811	Immunosurveillance: Innate and Adaptive Antitumor Immunity. 2007 , 29-41	
1810	Immune Escape: Immunosuppressive Networks. 2007 , 83-97	1
1809	Cytokine Regulation of Immune Tolerance to Tumors. 2007 , 43-61	1
1808	Altered macrophage differentiation and immune dysfunction in tumor development. 2007 , 117, 1155-66	899
1807	Modification of the tumor microenvironment to enhance immunity. 2007 , 12, 3576-600	39
1806	Naturally occurring regulatory T cells: recent insights in health and disease. 2007 , 27, 61-95	61
1805	The Links between Inflammation and Cancer. 2007 ,	
1804	Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. 2007 , 120, 2052-7	79
1803	CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. 2007 , 121, 95-105	174

1802	Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. 2007 , 120, 2723-33	226
1801	Immunotherapy with dendritic cells for prostate cancer. 2007 , 121, 467-73	31
1800	Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. 2008 , 122, 1030-9	83
1799	MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. 2008 , 122, 963-8	75
1798	Immune cells as anti-cancer therapeutic targets and tools. 2007 , 101, 918-26	18
1797	Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. 2007 , 71, 334-44	84
1796	CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. 2007 , 37, 282-91	30
1795	Induction of organ-selective CD4+ regulatory T cell homing. 2007 , 37, 978-89	101
1794	Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. 2007 , 37, 758-67	24
1793	Distinctive role of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets. 2007 , 37, 1575-83	121
1792	DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. 2007 , 37, 2378-89	543
1791	Manipulating the chemokine-chemokine receptor network to treat cancer. 2007 , 109, 2392-404	101
1790	Regulatory T cells and cancer. 2007 , 19, 217-23	274
1789	How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. 2007 , 247, 122-37	30
1788	The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. 2007 , 67, 623-9	28
1787	Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. 2007 , 67, 536-46	27
1786	The emerging roles of forkhead box (Fox) proteins in cancer. 2007 , 7, 847-59	809
1785	Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. 2007 , 7, 880-7	313

1784	Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. 2007 , 7, 41-51	1391
1783	International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China. 2007 , 14, 128-38	2
1782	Potential for stimulating host anti-tumor immune response via RNAi-mediated local FOXP3 knockdown. 2007 , 14, 519-20	1
1781	Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. 2007 , 14, 847-62	91
1780	Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. 2007 , 127, 2391-8	86
1779	Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. 2007 , 21, 472-9	45
1778	FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. 2007 , 21, 2512-8	122
1777	The impact of regulatory T cells on carcinogen-induced sarcogenesis. 2007 , 96, 1849-54	62
1776	Reply: Forkhead box P3-positive regulatory T cells in immune surveillance and cancer. 2007 , 97, 1017-1018	1
1775	Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. 2007 , 17, 627-37	26
1774	Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. 2007 , 87, 582-90	51
1773	Serum granulysin level as a novel prognostic marker in patients with gastric carcinoma. 2007 , 22, 1322-7	24
1772	Macrophage-derived chemokine in malignant and tuberculous pleural effusions. 2007 , 12, 581-4	8
1771	Potential functional role of plasmacytoid dendritic cells in cancer immunity. 2007 , 121, 149-57	34
1770	Regulatory T cells and tumour immunity - observations in mice and men. 2008 , 123, 157-63	86
1769	Regulatory T cells in health and disease. 2007 , 262, 78-95	55
1768	The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. 2007 , 137, 364-73	60
1767	Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. 2007 , 147, 395-400	14

1766	Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. 2007 , 150, 199-209	59
1765	Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. 2007 , 150, 523-30	96
1764	Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. 2007 , 98, 874-81	115
1763	The role of regulatory T cells in ovarian cancer. 2007 , 17, 764-70	13
1762	Taming cancer by inducing immunity via dendritic cells. 2007 , 220, 129-50	169
1761	Harnessing the immune system for ovarian cancer therapy. 2008 , 59, 62-74	20
1760	Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. 2007 , 5, 190-6	26
1759	Immuntherapie des Malignen Melanoms mit Dendritischen Zellen: Erfolge und Grenzen. 2007 , 5, ---	
1758	Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists. 2007 , 70, 268-72	13
1757	Challenges and prospects of immunotherapy as cancer treatment. 2007 , 1776, 108-23	27
1756	Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. 2007 , 1776, 160-74	22
1755	The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. 2007 , 125, 205-13	25
1754	Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes. 2007 , 35, 416-25	40
1753	Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. 2007 , 106, 75-81	58
1752	T regulatory cells: aid or hindrance in the clearance of disease?. 2007 , 11, 1291-325	11
1751	Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. 2007 , 17, 413-21	85
1750	Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. 2007 , 17, 459-68	44
1749	Review: chemokines in transplantation. 2007 , 21, 107-118	2

1748	The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. 2007 , 321, 107-20	21
1747	Poster 216: Combination of CTLs (CD8+/IFN) Reacted With Tumor Cells and Anti-CD25 mAb Provides Improved Immunotherapy for Tumors: An Animal Study. 2007 , 65, 43.e120	
1746	Interleukin-2 mastering regulation in cancer and autoimmunity. 2007 , 1107, 239-50	8
1745	Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. 2007 , 14, 2854-60	62
1744	Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation?. 2007 , 114, 9-15	33
1743	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. 2007 , 85, 1069-76	58
1742	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. 2007 , 56, 641-8	944
1741	In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. 2007 , 56, 927-38	43
1740	Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location. 2007 , 56, 1119-31	16
1739	Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. 2007 , 56, 1429-42	76
1738	Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. 2007 , 56, 1743-53	157
1737	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. 2007 , 56, 1513-37	130
1736	Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. 2007 , 56, 1687-700	155
1735	Tumor resistance to CD8+ T cell-based therapeutic vaccination. 2007 , 55, 205-17	7
1734	Inflammatory cell infiltration of tumors: Jekyll or Hyde. 2007 , 26, 373-400	237
1733	Effect of surgical resection of metastatic disease on immune tolerance to cancer. How a systemic disease could be controlled by a local therapy. 2007 , 9, 571-7	5
1732	Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. 2007 , 11, 596-602	46
1731	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. 2008 , 107, 249-57	140

1730	Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. 2008 , 109, 305-14	15
1729	Regulation and privilege in transplantation tolerance. 2008 , 28, 716-25	26
1728	The significance of Treg cells in defective tumor immunity. 2008 , 56, 181-91	55
1727	Regulatory CD4+CD25+ T cells and macrophages: communication between two regulators of effector T cells. 2008 , 57, 564-70	13
1726	Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. 2008 , 57, 123-31	185
1725	Immunological profiling of a panel of human ovarian cancer cell lines. 2008 , 57, 31-42	12
1724	Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. 2008 , 57, 813-21	107
1723	Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions. 2008 , 57, 951-61	18
1722	Dendritic cell vaccination and other strategies to tip the balance of the immune system : DC2007 5th International Meeting, July 16-18, Bamberg, Germany. 2008 , 57, 913-28	1
1721	Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. 2008 , 57, 1665-73	70
1720	Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration. 2008 , 57, 1745-56	19
1719	Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. 2008 , 57, 1531-9	24
1718	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. 2008 , 57, 1579-87	120
1717	Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. 2008 , 57, 1795-805	62
1716	Changes of CD4(+) CD25 (+) regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE. 2008 , 28, 645-8	7
1715	Immunoregulatory T cells: role and potential as a target in malignancy. 2008 , 10, 130-6	25
1714	Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis. 2008 , 41, 248-66	37
1713	Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. 2008 , 6, 20	9

1712	Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. 2008 , 28, 413-44	29
1711	Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. 2008 , 74, 227-35	25
1710	CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. 2008 , 122, 2286-93	252
1709	Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?. 2008 , 30, 251-61	42
1708	Dendritic cell vaccines in melanoma: from promise to proof?. 2008 , 66, 118-34	106
1707	Regulatory T cells and treatment of cancer. 2008 , 20, 241-6	214
1706	Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. 2008 , 116, 7-14	53
1705	The immune system--is it relevant to cancer development, progression and treatment?. 2008 , 20, 101-12	74
1704	Antigens for cancer immunotherapy. 2008 , 20, 286-95	131
1703	The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. 2008 , 13, 2177-90	6
1702	Immunotherapy of malignant brain tumors. 2008 , 222, 70-100	73
1701	Signaling defects in anti-tumor T cells. 2008 , 222, 192-205	78
1700	Cancer vaccines for established cancer: how to make them better?. 2008 , 222, 242-55	39
1699	The impact of T-cell immunity on ovarian cancer outcomes. 2008 , 222, 101-16	124
1698	Multiple roles for CD4+ T cells in anti-tumor immune responses. 2008 , 222, 129-44	334
1697	Antigen-specific immunotherapy of cervical and ovarian cancer. 2008 , 222, 43-69	54
1696	CD4+ T-regulatory cells: toward therapy for human diseases. 2008 , 223, 391-421	194
1695	Interleukin-10: new perspectives on an old cytokine. 2008 , 226, 205-18	751

1694	Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. 2008 , 60, 55-65	36
1693	Immunotherapy for advanced melanoma. 2008 , 128, 2596-2605	58
1692	Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. 2008 , 21, 1527-32	107
1691	Imaging in the era of molecular oncology. 2008 , 452, 580-9	1852
1690	International progress in cancer gene therapy. 2008 , 15, 765-75	36
1689	Toll-like receptors and immune regulation: implications for cancer therapy. 2008 , 27, 181-9	122
1688	TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. 2008 , 27, 168-80	138
1687	Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. 2008 , 221, 107-29	39
1686	Polarized immune responses differentially regulate cancer development. 2008 , 222, 145-54	146
1685	Strategies for use of IL-10 or its antagonists in human disease. 2008 , 223, 114-31	318
1684	How tumours escape mass destruction. 2008 , 27, 5894-903	145
1683	Positive and negative influences of regulatory T cells on tumour immunity. 2008 , 27, 5886-93	52
1682	The tumor microenvironment and its role in promoting tumor growth. 2008 , 27, 5904-12	1343
1681	Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. 2008 , 27, 5913-9	89
1680	A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. <i>Nature Medicine</i> , 2008 , 14, 258-65	50.5 145
1679	Inhibitory B7-family molecules in the tumour microenvironment. 2008 , 8, 467-77	1165
1678	From 'perfect mix' to 'potion magique'-- regulatory T cells and anti-inflammatory cytokines as adjuvant targets. 2008 , 6, C1; author reply C2	12
1677	The 'kiss of death' by dendritic cells to cancer cells. 2008 , 15, 58-69	54

1676	Tumor stress, cell death and the ensuing immune response. 2008 , 15, 21-8	68
1675	Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. 2008 , 15, 73-84	13
1674	Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. 2008 , 128, 676-84	25
1673	Analysis of splenic Gr-1 ^{int} immature myeloid cells in tumor-bearing mice. 2008 , 52, 47-53	18
1672	Depletion of CD4 ⁺ CD25 ⁺ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. 2008 , 152, 381-7	14
1671	Special regulatory T-cell review: T-cell dependent suppression revisited. 2008 , 123, 33-9	17
1670	Correlation of NK T-like CD3 ⁺ CD56 ⁺ cells and CD4 ⁺ CD25 ⁺ (hi) regulatory T cells with VEGF and TNF α in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. 2008 , 108, 421-7	71
1669	Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. 2008 , 109, 215-9	62
1668	The presence of tumor-infiltrating FOXP3 ⁺ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. 2008 , 110, 216-21	78
1667	FOXP3 ⁺ Tregs and B7-H1 ⁺ /PD-1 ⁺ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. 2008 , 8, 57	151
1666	Differential expression of CCR7 defines two distinct subsets of human memory CD4 ⁺ CD25 ⁺ Tregs. 2008 , 126, 291-302	43
1665	Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer. 2008 , 128, 205-18	9
1664	B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. 2008 , 129, 471-81	82
1663	FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. 2008 , 80, 483-9	24
1662	Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. 2008 , 1, 228-39	58
1661	Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. 2008 , 199, 35-45	74
1660	Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. 2008 , 135, 823-9	117
1659	Macrophage polarization in tumour progression. 2008 , 18, 349-55	863

1658	Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. 2008 , 129, 26-32	59
1657	Comparative methodologies of regulatory T cell depletion in a murine melanoma model. 2008 , 333, 167-79	77
1656	Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. 2008 , 75, 200-8	23
1655	Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. 2008 , 5, 531-40	60
1654	Regulatory T cells and multiple myeloma. 2008 , 8, 283-6	31
1653	Foxp3 expression in human cancer cells. 2008 , 6, 19	151
1652	Adjuvant therapy of melanoma with interferon: lessons of the past decade. 2008 , 6, 62	55
1651	Dendritic cells in cancer immunotherapy. 2008 , 99, 363-407	55
1650	Control of autoimmune diseases by the vitamin D endocrine system. 2008 , 4, 404-12	377
1649	Dendritic cell-based cancer vaccination: quo vadis?. 2008 , 7, 1041-53	19
1648	Ovarian Cancer. 2008 ,	2
1647	Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. 2008 , 14, 3254-61	314
1646	The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. 2008 , 111, 1472-9	65
1645	Tumor-specific regulatory T cells in cancer patients. 2008 , 69, 241-9	59
1644	Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens. 2008 , 69, 614-24	9
1643	[Systemic lupus erythematosus: news and therapeutic perspectives]. 2008 , 37, 444-59	4
1642	The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy. 2008 , 71, 527-9	3
1641	Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. 2008 , 46, 258-68	62

1640	Blood dendritic cells in patients with chronic lymphocytic leukaemia. 2008 , 213, 493-8	9
1639	Review of factors essential for blastocyst implantation for their modulating effects on the maternal immune system. 2008 , 19, 161-9	78
1638	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. 2008 , 20, 267-75	133
1637	Dendritic cell vaccines for the treatment of prostate cancer. 2008 , 26, 576-80	6
1636	Mechanisms of microRNA deregulation in human cancer. 2008 , 7, 2643-6	263
1635	FOXP3+ regulatory T cells as biomarkers in human malignancies. 2008 , 8, 1897-920	21
1634	Proteolytic processing of chemokines: implications in physiological and pathological conditions. 2008 , 40, 1185-98	85
1633	Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. 2008 , 44, 1875-82	156
1632	Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. 2008 , 138, 71-5	48
1631	Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. 2008 , 34, 173-9	72
1630	Targeting tumors with LIGHT to generate metastasis-clearing immunity. 2008 , 19, 285-94	46
1629	Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 2008 , 24, 577-90	7
1628	Statins, Tregs and cancer. 2008 , 196, 483-484	6
1627	Tumour immunity: effector response to tumour and role of the microenvironment. 2008 , 371, 771-83	415
1626	Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. 2008 , 22, 1373-9	115
1625	Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. 2008 , 8, 45-57	66
1624	A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. 2008 , 135, 234-43	618
1623	Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. 2008 , 9, 269-78	43

1622	Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?. 2008 , 55, 147-67, xi	3
1621	Immune privilege or privileged immunity?. 2008 , 1, 372-81	93
1620	Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. 2008 , 7, 1-5	31
1619	The role of NKT cells in tumor immunity. 2008 , 101, 277-348	220
1618	Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. 2008 , 26, 965-74	18
1617	The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. 2008 , 49, 1860-9	18
1616	Tumour-immune cell interactions modulated by chemokines. 2008 , 8, 269-90	35
1615	Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. 2008 , 7, 995-1003	11
1614	Promising particle-based vaccines in cancer therapy. 2008 , 7, 1103-19	50
1613	Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. 2008 , 12, 477-90	10
1612	Therapeutic human papillomavirus vaccines: current clinical trials and future directions. 2008 , 8, 421-39	132
1611	An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. 2008 , 14, 6116-24	20
1610	Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. 2008 , 205, 2221-34	188
1609	Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. 2008 , 14, 6674-82	394
1608	Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. 2008 , 180, 7338-48	119
1607	CCR5-dependent regulatory T cell migration mediates fungal survival and severe immunosuppression. 2008 , 180, 3049-56	75
1606	Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. 2008 , 180, 4679-86	74
1605	Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. 2008 , 181, 808-21	41

1604	Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. 2008 , 181, 7660-9	147
1603	Tumor microenvironment genesis and implications on cancer immune response. 2008 , 25-43	4
1602	The essential role of the in situ immune reaction in human colorectal cancer. 2008 , 84, 981-7	84
1601	Biological therapy with oncolytic herpesvirus. 2008 , 622, 221-33	7
1600	Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. 2008 , 57, 113-23	131
1599	Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. 2008 , 68, 5972-8	129
1598	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. 2008 , 14, 5242-9	91
1597	OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. 2008 , 68, 5206-15	124
1596	The local cytokine and chemokine milieu within malignant effusions. 2008 , 29, 93-104	22
1595	Current status of prognostic immunohistochemical markers for urothelial bladder cancer. 2008 , 29, 311-22	22
1594	Spontaneous and treatment-induced cancer rejection in humans. 2008 , 8, 337-49	13
1593	The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. 2008 , 14, 8228-35	151
1592	Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. 2008 , 98, 148-53	110
1591	Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. 2008 , 98, 1258-63	49
1590	In Reply. 2008 , 26, 1563-1563	
1589	T-cell responses to survivin in cancer patients undergoing radiation therapy. 2008 , 14, 4883-90	114
1588	Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. 2008 , 14, 6770-9	108
1587	Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. 2008 , 14, 7652-8	19

1586	Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. 2008 , 181, 3099-107	466
1585	Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. 2008 , 181, 6283-92	59
1584	Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. 2008 , 105, 15505-10	230
1583	Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. 2008 , 180, 2967-80	125
1582	Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata. 2008 , 180, 7681-6	38
1581	CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis. 2008 , 181, 1806-13	85
1580	TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. 2008 , 181, 3784-92	158
1579	In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. 2008 , 181, 126-35	56
1578	Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. 2008 , 180, 5871-81	25
1577	In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. 2008 , 105, 10221-6	111
1576	An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. 2008 , 68, 4893-901	15
1575	Recent Advances in T Cell Adoptive Immunotherapy of Cancer. 2008 , 4, 1-13	1
1574	CD4+CD25+ regulatory T cells in the small intestinal lamina propria show an effector/memory phenotype. 2008 , 20, 307-15	44
1573	Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. 2008 , 14, 2413-20	227
1572	Characterization of a lymphocyte subset displaying a unique regulatory activity in human decidua. 2008 , 20, 1147-54	11
1571	Principles of Molecular Oncology. 2008 ,	1
1570	Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. 2008 , 118, 3367-77	407
1569	Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. 2008 , 14, 2028-35	176

1568	Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. 2008 , 8, 68-75	10
1567	Targeted therapies to improve tumor immunotherapy. 2008 , 14, 4385-91	81
1566	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. 2008 , 205, 2125-38	167
1565	Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. 2008 , 14, 5166-72	227
1564	T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. 2008 , 14, 3706-15	125
1563	Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. 2008 , 14, 2740-8	85
1562	Effects of chemoradiation on tumor-host interactions: the immunologic side. 2008 , 26, 1562-3; author reply 1563	31
1561	Overcoming immunosuppressive mechanisms. 2008 , 19 Suppl 7, vii241-7	10
1560	Ectopic lymph nodes within human solid tumors. 2008 , 26, 4369-70	26
1559	Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. 2008 , 181, 4733-41	367
1558	The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. 2008 , 68, 3001-9	144
1557	Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. 2008 , 14, 1032-40	120
1556	Foxp3 and microsatellite stability phenotype in colorectal cancer. 2008 , 57, 725-6	7
1555	Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. 2008 , 14, 2310-7	165
1554	Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. 2008 , 68, 292-300	56
1553	Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. 2008 , 68, 5948-54	69
1552	OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. 2008 , 205, 825-39	315
1551	Exosomes for the treatment of human malignancies. 2008 , 40, 82-8	24

1550	T-regulatory cells in tumour-specific vaccination strategies. 2008 , 8, 1365-79	16
1549	Advances in tumour immunotherapy. 2008 , 101, 675-83	22
1548	CD4+ CD25+ regulatory T cells: a therapeutic target for liver diseases. 2008 , 12, 313-26	4
1547	Regulatory T cells as therapeutic target in Hodgkin's lymphoma. 2008 , 12, 769-82	14
1546	Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?. 2008 , 8, 232-9	14
1545	Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10. 2008 , 37, 315-38	6
1544	Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. 2008 , 111, 219-28	270
1543	Immunotherapy opportunities in ovarian cancer. 2008 , 8, 243-57	52
1542	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. 2008 , 111, 5610-20	225
1541	IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. 2008 , 111, 229-35	122
1540	Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis. 2008 , 111, 761-6	39
1539	Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. 2008 , 111, 5359-70	99
1538	Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. 2008 , 111, 1404-12	27
1537	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. 2008 , 112, 1175-83	196
1536	Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. 2008 , 112, 610-8	255
1535	FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. 2008 , 112, 2858-68	85
1534	FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. 2008 , 112, 4953-60	116
1533	[Importance of HLA-G in therapy of cancer]. 2008 , 63, 327-32	

1532	Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines. 2008 , 4, 161-165	
1531	Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. 2008 , 31, 189-98	58
1530	Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. 2008 , 8, 208-21	28
1529	An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. 2008 , 31, 820-9	39
1528	Differential impact of CD154 costimulation blockade on alloreactive effector and regulatory T cells in murine renal transplant recipients. 2008 , 85, 1332-8	25
1527	Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. 2008 , 86, 137-47	58
1526	CD4+CD25+ regulatory T lymphocytes in tuberculous pleural effusion. 2008 , 121, 581-586	24
1525	Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. 2008 , 28, 109-26	126
1524	T lymphocytes in pleural effusion. 2008 , 121, 579-580	14
1523	. 2008 ,	0
1522	The role of T-regulatory cells in pregnancy and cancer. 2008 , 13, 2275-89	29
1521	Molecular Pathogenesis of Epithelial Ovarian Cancer. 2008 , 441-454	1
1520	Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy. 2008 ,	1
1519	Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. 2008 , 3, e3409	35
1518	Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. 2008 , 49, 942-8	20
1517	Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex. 2008 , 13, 3986-4001	30
1516	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. 2008 , 118, 3751-61	52
1515	Chemokines: coded messages for T-cell missions. 2008 , 13, 6341-53	24

1514	Tumor and immunity. 2009 , 45, 162	3
1513	The role of regulatory T cells in cancer. 2009 , 9, 209-35	69
1512	Cancer Vaccines: Some Basic Considerations. 2009 , 573-589	
1511	Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. 2009 , 4, e4749	81
1510	A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. 2009 , 4, e5061	56
1509	Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. 2009 , 4, e6412	285
1508	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. 2009 , 14, 1761-70	50
1507	Hyperthermia and irradiation of head and neck squamous cancer cells causes migratory profile changes of tumour infiltrating lymphocytes. 2009 , 25, 347-54	11
1506	Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. 2009 , 69, 8085-93	37
1505	Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells. 2009 , 50, 2377-88	68
1504	NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. 2009 , 15, 2130-9	68
1503	The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. 2009 , 182, 3349-56	72
1502	Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. 2009 , 183, 4848-52	63
1501	Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. 2009 , 69, 1587-95	81
1500	Elite control of HIV infection: implications for vaccine design. 2009 , 9, 55-69	85
1499	Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. 2009 , 183, 3720-30	381
1498	Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. 2009 , 15, 3325-32	207
1497	RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. 2009 , 182, 6079-87	53

1496	Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. 2009 , 182, 6095-104	40
1495	Anti-CTLA-4 therapy results in higher CD4+ICOS ^{hi} T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. 2009 , 106, 2729-34	157
1494	Neuromodulatory activities of CD4+CD25 ⁺ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. 2009 , 182, 3855-65	71
1493	Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. 2009 , 182, 4675-85	31
1492	Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. 2009 , 183, 4782-91	57
1491	FoxP3 ⁺ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. 2009 , 179, 1061-70	315
1490	T-regulatory cell modulation: the future of cancer immunotherapy?. 2009 , 100, 1697-703	77
1489	Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. 2009 , 101, 1513-21	74
1488	Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. 2009 , 9, 1499-510	20
1487	Immunoregulation through IL-10 gene expression and the fate of cytotoxic T lymphocyte-mediated tumor immunotherapy. 2009 , 15, 3-8	1
1486	Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. 2009 , 69, 3205-12	94
1485	Human circulating CD4 ⁺ CD25 ^{high} Foxp3 ⁺ regulatory T cells kill autologous CD8 ⁺ but not CD4 ⁺ responder cells by Fas-mediated apoptosis. 2009 , 182, 1469-80	142
1484	OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. 2009 , 182, 1481-9	32
1483	Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. 2009 , 182, 1746-55	291
1482	FOXP3 expression and prognosis: role of both the tumor and T cells. 2009 , 27, 1735-6	18
1481	Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. 2009 , 20, 1688-96	40
1480	Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. 2009 , 106, 19455-60	53
1479	B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer. 2009 , 15, 960-70	10

1478	FOXP3 defines regulatory T cells in human tumor and autoimmune disease. 2009 , 69, 3995-4000	163
1477	Renal Cell Carcinoma. 2009 ,	3
1476	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. 2009 , 206, 1103-16	174
1475	Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. 2009 , 69, 5996-6004	212
1474	Differences in tumor regulatory T-cell localization and activation status impact patient outcome. 2009 , 69, 7895-8	91
1473	Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. 2009 , 15, 1046-51	106
1472	Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. 2009 , 15, 6881-90	36
1471	Revisiting the prognostic value of regulatory T cells in patients with cancer. 2009 , 27, e5-6; author reply e7	33
1470	Cellular immunotherapy for ovarian cancer. 2009 , 9, 677-88	25
1469	Expression profile of microRNA in epithelial cancer: diagnosis, classification and prediction. 2009 , 3, 25-36	3
1468	Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors. 2009 , 8, 707-13	5
1467	CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. 2009 , 8, 2578-85	25
1466	Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. 2009 , 8, 66-72	26
1465	Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. 2009 , 35, 741-9	53
1464	A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. 2009 ,	2
1463	Chemokine-chemokine receptors in cancer immunotherapy. 2009 , 1, 109-27	21
1462	Promising novel immunotherapies and combinations for prostate cancer. 2009 , 5, 187-96	22
1461	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. 2009 , 18, 1001-11	161

1460	Regulatory T cells: major players in the tumor microenvironment. 2009 , 15, 1879-92	64
1459	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. 2009 , 1, 845-53	13
1458	Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. 2009 , 9, 113-31	27
1457	Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease. 2009 , 1, 163-5	4
1456	Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. 2009 , 9, 541-65	14
1455	The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. 2009 , 24, 357-67	32
1454	Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. 2009 , 48, 391-400	30
1453	Solid tumors in adults. 2009 , 137-145	
1452	The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. 2009 , 5, e1000637	126
1451	Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. 2009 , 15, 2166-73	111
1450	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. 2009 , 27, 5911-8	178
1449	PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. 2009 , 21, 1065-77	230
1448	Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. 2009 , 15, 1052-8	72
1447	Combination approaches to immunotherapy: the radiotherapy example. 2009 , 1, 1025-37	26
1446	NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. 2009 , 182, 2753-65	58
1445	CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. 2009 , 69, 6331-8	46
1444	Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses. 2009 , 15, 2756-66	9
1443	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. 2009 , 11, 394-402	164

1442	Reply to C. Badoual et al. 2009 , 27, e7-e7	14
1441	Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. 2009 , 183, 6330-7	50
1440	CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. 2009 , 15, 2231-7	66
1439	Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. 2009 , 69, 599-608	263
1438	Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. 2009 , 183, 6939-47	73
1437	Tricks tumors use to escape from immune control. 2009 , 45, e119-23	35
1436	Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. 2009 , 45, e167-74	78
1435	Suppressing the suppressor: Role of immunosuppressive regulatory T cells in cancer surgery. 2009 , 145, 345-50	2
1434	Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. 2009 , 9, 170	19
1433	Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. 2009 , 9, 231	80
1432	Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. 2009 , 9, 292	128
1431	ProtEx technology for the generation of novel therapeutic cancer vaccines. 2009 , 86, 198-207	6
1430	Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. 2009 , 114, 105-10	122
1429	Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. 2009 , 115, 185-92	152
1428	Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient. 2009 , 9, 1253	1
1427	CCR5 is required for regulation of alloreactive T-cell responses to single class II MHC-mismatched murine cardiac grafts. 2009 , 9, 2251-61	12
1426	Tumor-associated macrophages: effectors of angiogenesis and tumor progression. 2009 , 1796, 11-8	179
1425	Stored red blood cell transfusion induces regulatory T cells. 2009 , 208, 110-9	62

1424	FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. 2009 , 131, 1-10	28
1423	Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. 2009 , 133, 333-52	33
1422	Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. 2009 , 27, 31-9	126
1421	Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. 2009 , 124, 239-44	61
1420	Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. 2009 , 124, 2353-60	25
1419	Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. 2009 , 125, 1092-101	80
1418	A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. 2009 , 125, 879-86	44
1417	Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. 2009 , 125, 1372-9	94
1416	Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. 2009 , 125, 1640-8	186
1415	Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. 2009 , 125, 2104-13	111
1414	Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model. 2009 , 125, 2871-8	4
1413	A specific cytotoxic T-lymphocyte epitope presentation system for antitumor immunity. 2010 , 126, 2373-86	4
1412	Regulatory T cells control macrophage accumulation and activation in lymphoma. 2010 , 127, 1131-40	21
1411	Genetic polymorphism in chemokine CCL22 and susceptibility to Helicobacter pylori infection-related gastric carcinoma. 2009 , 115, 2430-7	14
1410	Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. 2009 , 115, 2891-902	90
1409	Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. 2009 , 75, 175-88	66
1408	Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. 2009 , 39, 241-53	45
1407	Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. 2009 , 39, 1323-33	31

1406	Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity. 2009 , 39, 2703-15	26
1405	VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. 2010 , 40, 197-203	84
1404	Toward effective immunotherapy for the treatment of malignant brain tumors. 2009 , 6, 527-38	33
1403	Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. 2009 , 124, 1-8	30
1402	The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. 2009 , 26 Suppl 1, 3-12	14
1401	When neighbourhood matters: tumour microenvironment. 2009 , 11, 70-4	5
1400	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. 2009 , 3, 173-186	
1399	The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate. 2009 , 4, 196-201	5
1398	Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. 2009 , 87, 595-612	10
1397	The development and function of regulatory T cells. 2009 , 66, 2603-22	196
1396	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. 2009 , 58, 449-59	292
1395	The immunosuppressive tumor microenvironment in hepatocellular carcinoma. 2009 , 58, 877-86	38
1394	The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. 2009 , 58, 1033-45	309
1393	Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity. 2009 , 58, 1057-69	22
1392	Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. 2009 , 58, 1195-206	101
1391	TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. 2009 , 58, 801-8	40
1390	Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. 2009 , 58, 1363-73	65
1389	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. 2009 , 58, 1627-34	174

1388	Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). 2009 , 58, 1657-67	25
1387	Vaccination strategies in patients with renal cell carcinoma. 2009 , 58, 1169-74	26
1386	On the origin of serum CD26 and its altered concentration in cancer patients. 2009 , 58, 1723-47	158
1385	Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. 2009 , 9, 65	118
1384	Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. 2009 , 7, 12	11
1383	Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro. 2009 , 100, 2143-51	15
1382	CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alpha-betaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. 2009 , 144, 686-95	116
1381	Regulatory T cells and asthma. 2009 , 39, 1314-23	160
1380	Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. 2009 , 156, 344-52	3
1379	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. 2009 , 157, 9-19	111
1378	Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. 2009 , 6, 3-13	67
1377	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. 2009 , 22, 393-402	196
1376	Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 2009 , 16, 900-11	44
1375	Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenic assessment and prognostic impact. 2009 , 101, 1869-75	23
1374	Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. 2010 , 19, e213-21	34
1373	Inverse correlation between NKG2D expression on CD8+ T cells and the frequency of CD4+CD25+ regulatory T cells in patients with esophageal cancer. 2009 , 22, 49-54	8
1372	T cell-mediated immunoregulation in the gastrointestinal tract. 2009 , 64, 505-19	64
1371	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. 2009 , 74, 1-10	12

1370	Statins, regulatory T cells, and pediatric graft coronary artery disease. 2009 , 13, 139-40	2
1369	The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. 2009 , 103, 399-405	69
1368	Antitumor immunity and cancer stem cells. 2009 , 1176, 154-69	123
1367	Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. 2009 , 1174, 99-106	220
1366	In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. 2009 , 156, 297-306	24
1365	Protease-activated receptors and prostaglandins in inflammatory lung disease. 2009 , 158, 1017-33	41
1364	B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. 2009 , 33, 948-57	36
1363	Dendritic cells from bench to bedside and back. 2009 , 122, 128-30	76
1362	Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. 2009 , 30, 899-911	1576
1361	Nanomolecular targeting of dendritic cells for ovarian cancer therapy. 2009 , 5, 1189-92	16
1360	Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. 2009 , 69, 8412-9	77
1359	Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. 2009 , 69, 2000-9	489
1358	Improving the efficacy of cancer immunotherapy. 2009 , 45, 1424-31	39
1357	Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. 2009 , 45, 2123-31	46
1356	Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. 2009 , 35, 1268-72	17
1355	Immunomodulation of a prophylactic human papilloma virus vaccine to be effective therapeutically. 2009 , 2, 107-108	
1354	Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. 2009 , 279, 1-7	121
1353	Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen. 2009 , 285, 66-72	25

1352	Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferation. 2009 , 23, 1028-37	13
1351	B7-H4 transfection prolongs beta-cell graft survival. 2009 , 21, 143-9	27
1350	Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. 2009 , 27, 684-9	35
1349	In situ adenovirus vaccination engages T effector cells against cancer. 2009 , 27, 4225-39	40
1348	TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. 2009 , 30, 439-46	118
1347	Increased survival from stage IV melanoma associated with fewer regulatory T Cells. 2009 , 154, 13-20	27
1346	Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. 2009 , 70, 345-52	150
1345	Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment. 2009 , 70, 430-5	31
1344	The double-edged sword of statin immunomodulation. 2009 , 135, 128-30	37
1343	Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. 2009 , 50, 980-9	396
1342	Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. 2009 , 46, 893-901	33
1341	Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. 2009 , 54, 31-7	11
1340	Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. 2009 , 5, 379-90	57
1339	OX40 (CD134) and OX40L. 2009 , 647, 94-107	27
1338	Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. 2009 , 137, 1270-9	229
1337	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. 2009 , 7, 49	47
1336	Immune therapy for cancer. 2009 , 27, 83-117	476
1335	Dendritic Cells in Cancer. 2009 ,	1

1334	Lenalidomide: a novel anticancer drug with multiple modalities. 2009 , 10, 125-33	54
1333	Role of Regulatory Subsets During Aging. 2009 , 343-377	1
1332	Tumor vaccines for breast cancer. 2009 , 27, 361-8	33
1331	Immunotherapy in renal cell carcinoma. 2009 , 1, 97-107	5
1330	Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?. 2009 , 11, R153	61
1329	Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. 2009 , 9, 1317-32	50
1328	Frequency and gene expression profile of regulatory T cells in renal cell carcinoma. 2009 , 30, 160-70	17
1327	Dendritic Cells. 2009 ,	2
1326	Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion. 2009 , 2, 291-9	15
1325	Induction of tolerogenic dendritic cells by vitamin D receptor agonists. 2009 , 251-73	74
1324	Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. 2009 , 58, 520-9	191
1323	Dendritic cell vaccination as a treatment modality for melanoma. 2009 , 9, 1631-42	17
1322	Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. 2009 , 69, 2896-901	67
1321	High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. 2009 , 27, 1470-6	245
1320	Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. 2009 , 50, 788-801	91
1319	Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. 2009 , 27, 186-92	752
1318	Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. 2009 , 50, 571-81	7
1317	Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity. 2009 , 50, 687-8	15

1316	Combined intratumoral regulatory T-cell depletion and transforming growth factor- β neutralization induces regression of established AE17 murine mesothelioma tumors. 2009 , 29, 209-15	6
1315	Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. 2009 , 175, 1525-35	60
1314	Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. 2009 , 86, 1065-73	979
1313	Anti-inflammatory agents as cancer therapeutics. 2009 , 57, 31-89	61
1312	Changes in regulatory T cells in dogs with cancer and associations with tumor type. 2009 , 23, 875-81	55
1311	Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. 2009 , 57, 409-23	13
1310	Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. 2009 , 27, 945-52	119
1309	Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. 2009 , 32, 101-8	52
1308	Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. 2009 , 32, 498-507	219
1307	Ovarian cancer-derived glycodelin impairs in vitro dendritic cell maturation. 2009 , 32, 492-7	8
1306	New therapeutic agents in ovarian cancer. 2009 , 21, 44-53	16
1305	Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. 2009 , 32, 12-21	112
1304	The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. 2009 , 32, 22-8	67
1303	Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. 2009 , 32, 887-94	31
1302	Current developments with peptide-based human tumor vaccines. 2009 , 21, 524-30	20
1301	Regulatory T cells actively infiltrate metastatic brain tumors. 2009 , 34, 1533-40	26
1300	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. 2009 , 113, 6392-402	376
1299	Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. 2009 , 113, 1681-8	27

1298	Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. 2009 , 113, 5330-9	13
1297	The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 2009 , 113, 2394-401	194
1296	Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. 2009 , 113, 3542-5	127
1295	Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. 2009 , 113, 3139-46	179
1294	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. 2009 , 114, 1141-9	579
1293	Double jeopardy. 2009 , 114, 1135-6	1
1292	Th17 cells in ovarian cancer. 2009 , 114, 1134-5	23
1291	Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. 2009 , 19, 1329-34	28
1290	Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer. 2009 , 22, 1459-71	13
1289	Chemokine receptors as targets for cancer therapy. 2009 , 15, 742-57	65
1288	Antibody-drug conjugate targets. 2009 , 9, 982-1004	121
1287	Suppressive influences in the immune response to cancer. 2009 , 32, 1-11	62
1286	Targeting the immune system in cancer. 2009 , 10, 166-84	51
1285	Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development. 2009 , 9, 151-77	6
1284	Behavior of immune players in the tumor microenvironment. 2009 , 21, 53-9	59
1283	Juxtatumoral stromal reactions in uterine endometrioid adenocarcinoma and their prognostic significance. 2010 , 29, 562-7	6
1282	HPV and Therapeutic Vaccines: Where are We in 2010?. 2010 , 6, 81-103	31
1281	Regulatory T cells and skin tumors. 2010 , 4, 249-54	7

1280	Metabolic immune restraints: implications for anticancer vaccines. 2010 , 16, 277-91	1
1279	Drug-mediated and cellular immunotherapy in multiple myeloma. 2010 , 2, 243-55	10
1278	Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. 2010 , 90, 540-6	53
1277	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. 2010 , 33, 435-41	173
1276	Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. 2010 , 33, 547-56	51
1275	A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. 2010 , 33, 991-8	161
1274	Current status of immunological therapies for prostate cancer. 2010 , 20, 241-6	36
1273	Regulatory T cells: overcoming suppression of T-cell immunity. 2010 , 16, 342-7	37
1272	Mechanism analysis of long-term graft survival by monocarboxylate transporter-1 inhibition. 2010 , 90, 1299-306	2
1271	Tumor-specific crosslinking of GITR as costimulation for immunotherapy. 2010 , 33, 925-34	14
1270	Renal cell carcinoma may evade the immune system by converting CD4+Foxp3- T cells into CD4+CD25+Foxp3+ regulatory T cells: Role of tumor COX-2-derived PGE2. 2010 , 3, 959-63	12
1269	Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. 2010 , 36, 841-8	34
1268	T regulatory cell markers in oral squamous cell carcinoma: Relationship with survival and tumor aggressiveness. 2010 , 1, 127-132	18
1267	Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. 2010 , 26, 67-75	36
1266	Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. 2010 , 115, 965-74	300
1265	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. 2010 , 115, 289-95	145
1264	Interface of signal transduction inhibition and immunotherapy in melanoma. 2010 , 16, 360-6	8
1263	Immunophysiological mechanisms of the origin and maintenance of tumor growth in humans. 2010 , 36, 373-381	2

1262	Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. 2010 , 17, 718-30	388
1261	Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients. 2010 , 30, 43-8	12
1260	Cytokine regulation of natural killer cell effector functions. 2010 , 36, 274-88	110
1259	Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. 2010 , 59, 599-607	32
1258	Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. 2010 , 59, 653-61	123
1257	Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. 2010 , 59, 769-77	46
1256	Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function. 2010 , 59, 779-87	6
1255	Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. 2010 , 59, 909-19	49
1254	New strategies for the manipulation of adaptive immune responses. 2010 , 59, 1443-8	12
1253	Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma. 2010 , 59, 1411-6	
1252	Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer. 2010 , 59, 1813-23	3
1251	Regulatory T cells in peripheral blood, lymph node, and thyroid tissue in patients with medullary thyroid carcinoma. 2010 , 34, 1481-7	11
1250	Regulatory T cell as a target for cancer therapy. 2010 , 58, 179-90	25
1249	Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. 2010 , 58, 335-46	9
1248	Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers. 2010 , 456, 615-23	8
1247	Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14?/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. 2010 , 136, 35-45	238
1246	Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. 2010 , 136, 1585-95	155
1245	Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. 2010 , 136, 1745-54	70

1244	Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. 2010 , 15, 552-8	46
1243	Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma. 2010 , 17, 892-7	7
1242	Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. 2010 , 45, 968-78	38
1241	T cell density and location can influence the prognosis of ovarian cancer. 2010 , 16, 361-70	11
1240	FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. 2010 , 16, 303-9	44
1239	T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. 2010 , 3, 29-47	45
1238	Regulatory T cells and immune tolerance to tumors. 2010 , 46, 79-93	55
1237	Low molecular weight fraction secreted by SKOV3 cells expands peripheral CD4+CD25+ regulatory T cells and enhances their suppressive capacity. 2010 , 27, 600-6	1
1236	N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine. 2010 , 15, 631-8	7
1235	Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. 2010 , 28, 887-94	40
1234	Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. 2010 , 37, 473-84	184
1233	Large scale preparation of human MHC class II+ integrin beta(1)+ Tregs. 2010 , 360, 96-102	1
1232	Prognostic significance and mechanism of Treg infiltration in human brain tumors. 2010 , 225, 195-9	152
1231	T-cell function in chronic lymphocytic leukaemia. 2010 , 20, 431-8	38
1230	Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. 2010 , 10, 82	29
1229	Ovarian cancer immunotherapy: opportunities, progresses and challenges. 2010 , 3, 7	48
1228	T regulatory cells, the evolution of targeted immunotherapy. 2010 , 1806, 7-17	19
1227	Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization. 2010 , 262, 150-61	27

1226	Dendritic cells pulsed with an anti-idiotypic antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice. 2010 , 263, 9-21	13
1225	Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. 2010 , 134, 277-88	114
1224	Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. 2010 , 135, 466-75	66
1223	Human retinal pigment epithelium-induced CD4+CD25+ regulatory T cells suppress activation of intraocular effector T cells. 2010 , 136, 83-95	29
1222	Phase II trial of GM-CSF in women with asymptomatic recurrent mÜlerian tumors. 2010 , 116, 168-72	8
1221	The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. 2010 , 116, 222-33	28
1220	Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. 2010 , 116, 556-62	56
1219	Ovarian cancer creates a suppressive microenvironment to escape immune elimination. 2010 , 117, 366-72	114
1218	Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. 2010 , 14, 426-33	41
1217	Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. 2010 , 14, 2748-59	43
1216	Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. 2010 , 116, 2224-33	79
1215	Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. 2010 , 32, 946-58	42
1214	Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. 2011 , 33, 415-23	32
1213	Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. 2010 , 126, 2143-52	23
1212	Unifying roles for regulatory T cells and inflammation in cancer. 2010 , 126, 1651-65	60
1211	High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. 2010 , 126, 2635-43	240
1210	ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients. 2010 , 127, 1412-20	61
1209	NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. 2010 , 127, 2598-611	16

1208	Regulatory T cells in tumor immunity. 2010 , 127, 759-67	621
1207	Prognostic significance of regulatory T cells in tumor. 2010 , 127, 748-58	83
1206	Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. 2010 , 40, 1099-106	157
1205	Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. 2010 , 40, 3325-35	99
1204	Exosomes: extracellular organelles important in intercellular communication. 2010 , 73, 1907-20	1688
1203	Uptake and distribution of labeled antibodies into pH-sensitive microgels. 2010 , 6, 2148-56	9
1202	Natural immunity to cancer in humans. 2010 , 22, 215-22	129
1201	Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. 2010 , 22, 583-91	67
1200	Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. 2010 , 127, 77-84	93
1199	A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation. 2010 , 8, 7	19
1198	Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. 2010 , 28, 620-32	110
1197	The biologic importance of tumor-infiltrating lymphocytes. 2010 , 37 Suppl 1, 48-53	31
1196	Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. 2010 , 101, 1947-54	125
1195	Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR ^{low} myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. 2010 , 72, 540-7	158
1194	Poster Abstracts. 2010 , 131, 52-190	1
1193	Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. 2010 , 161, 298-305	22
1192	Immune infiltration in human tumors: a prognostic factor that should not be ignored. 2010 , 29, 1093-102	725
1191	Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. 2010 , 103, 685-92	35

1190	Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. 2010 , 103, 693-700	157
1189	Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. 2010 , 7, 306-15	119
1188	Lentiviral-mediated Foxp3 RNAi suppresses tumor growth of regulatory T cell-like leukemia in a murine tumor model. 2010 , 17, 972-9	10
1187	B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. 2010 , 24, 1186-96	64
1186	Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. 2010 , 11, 889-96	2436
1185	T(H)17 cells in tumour immunity and immunotherapy. 2010 , 10, 248-56	460
1184	Monoclonal antibodies: versatile platforms for cancer immunotherapy. 2010 , 10, 317-27	879
1183	FOXP3+ regulatory T cells in the human immune system. 2010 , 10, 490-500	1713
1182	The polarization of immune cells in the tumour environment by TGFbeta. 2010 , 10, 554-67	633
1181	Les lymphocytes T régulateurs et les lymphocytes Th17 : fonctions physiologiques et pathologiques. 2010 , 2010, 31-40	
1180	CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. 2010 , 23, 422-9	48
1179	CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies. 2010 , 2, 980-92	28
1178	Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. 2010 , 25	4
1177	Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. 2010 , 2, 913-54	20
1176	Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. 2010 , 2010, 426956	54
1175	Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). 2010 , 5, e11469	304
1174	Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice. 2010 , 5, e10357	24
1173	Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. 2010 , 5, e10436	194

1172	Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. 2010 , 5, e10471	42
1171	Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta. 2010 , 5, e12281	20
1170	T regulatory cells in cord blood--FOXP3 demethylation as reliable quantitative marker. 2010 , 5, e13267	44
1169	Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells. 2010 , 5, e13623	13
1168	Prolonged survival of allografts induced by mycobacterial Hsp70 is dependent on CD4+CD25+ regulatory T cells. 2010 , 5, e14264	34
1167	Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma. 2010 , 21, 38-44	3
1166	Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma. 2010 , 21, 132	1
1165	Immunoregulatory cells of the tumor microenvironment. 2010 , 15, 291-308	6
1164	Immunotoxicology of Pesticides and Chemotherapies. 2010 , 467-487	3
1163	In Vivo Scintigraphic Imaging of Antitumor Effects by Combined Radioiodine Therapy and Human Sodium Iodide Symporter Gene Immunotherapy. 2010 , 9, 7290.2010.00010	
1162	Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. 2010 , 16, 5067-78	185
1161	Differential heat shock protein localization in chronic lymphocytic leukemia. 2010 , 87, 467-76	20
1160	Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. 2010 , 285, 7176-86	281
1159	Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. 2010 , 16, 1662-72	200
1158	Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. 2010 , 185, 1450-9	42
1157	Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. 2010 , 70, 9599-610	96
1156	Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. 2010 , 16, 3594-606	103
1155	Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. 2010 , 185, 956-66	25

1154	Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. 2010 , 185, 7165-73	49
1153	Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. 2010 , 185, 2895-902	14
1152	Differential suppression of tumor-specific CD8+ T cells by regulatory T cells. 2010 , 185, 5048-55	17
1151	Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. 2010 , 3, 1265-76	25
1150	Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. 2010 , 107, 8736-41	82
1149	DNA vaccines: developing new strategies against cancer. 2010 , 2010, 174378	118
1148	Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. 2010 , 2010, 791603	37
1147	Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. 2010 , 185, 4063-71	97
1146	A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. 2010 , 185, 5150-9	79
1145	Disappearing myelodysplastic syndrome-associated hemolytic anemia in leukemic transformation. 2010 , 152, 407-12	4
1144	Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma. 2010 , 22, 438-41	38
1143	Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. 2010 , 184, 6709-18	33
1142	Mechanisms of immune suppression exerted by regulatory T-cells in subcutaneous AE17 murine mesothelioma. 2010 , 30, 829-34	4
1141	Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. 2010 , 185, 7199-206	35
1140	Unravelling the complexity of cancer-immune system interplay. 2010 , 10, 917-34	4
1139	Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. 2010 , 10, 1019-35	73
1138	Mechanisms of T-cell inhibition: implications for cancer immunotherapy. 2010 , 9, 89-105	22
1137	Redirecting the immune response: role of adoptive T cell therapy. 2010 , 21, 533-41	8

1136	Emerging drugs for ovarian cancer. 2010 , 15, 635-52	4
1135	Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells. 2010 , 185, 6698-705	43
1134	Tumor microenvironments direct the recruitment and expansion of human Th17 cells. 2010 , 184, 1630-41	256
1133	Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. 2010 , 185, 6734-40	48
1132	Biology and clinical observations of regulatory T cells in cancer immunology. 2011 , 344, 61-95	27
1131	Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. 2010 , 29, 461-84	5
1130	LAG-3 expression defines a subset of CD4(+)/CD25(high)/Foxp3(+) regulatory T cells that are expanded at tumor sites. 2010 , 184, 6545-51	209
1129	Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)/Gr-1(+) cells. 2010 , 184, 6151-60	39
1128	Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. 2010 , 184, 2886-98	163
1127	Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. 2010 , 185, 174-82	96
1126	Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. 2010 , 16, 255-67	25
1125	Sliding set-points of immune responses for therapy of autoimmunity. 2010 , 207, 1819-23	5
1124	Vaccine prevention of cancer: can endogenous antigens be targeted?. 2010 , 3, 410-5	20
1123	Immunomodulatory effects of radiofrequency ablation in a breast cancer model. 2010 , 39, 74-92	15
1122	Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. 2010 , 95, 2325-33	100
1121	T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. 2010 , 2010, 236378	29
1120	Vaccines against human carcinomas: strategies to improve antitumor immune responses. 2010 , 2010, 380697	35
1119	4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. 2010 , 70, 3945-54	46

1118	Combination of adoptive cell transfer and antibody injection can eradicate established tumors in mice--an in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb. 2010 , 32, 238-45	9
1117	Expression profiling of genes associated with regulatory functions of T-cell subsets in Marek's disease virus-infected chickens. 2010 , 39, 367-73	12
1116	T regulatory cells in cancer: recent advances and therapeutic potential. 2010 , 10, 1573-86	85
1115	Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. 2010 , 51, 2021-30	8
1114	Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. 2010 , 18, 1233-43	77
1113	Immunotherapy for renal cell carcinoma. 2010 , 2010, 284581	50
1112	Immune suppression in head and neck cancers: a review. 2010 , 2010, 701657	120
1111	Biological rationales and clinical applications of temperature controlled hyperthermia--implications for multimodal cancer treatments. 2010 , 17, 3045-57	61
1110	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. 2010 , 9, 260-8	35
1109	Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. 2010 , 16, 1520-31	185
1108	Premetastatic milieu explained by TLR4 agonist-mediated homeostatic inflammation. 2010 , 7, 94-9	5
1107	Personalized dendritic cell-based tumor immunotherapy. 2010 , 2, 57-68	51
1106	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. 2010 , 23, 1104-12	162
1105	Roles for inflammation and regulatory T cells in colon cancer. 2010 , 38, 76-87	86
1104	Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. 2010 , 341, 121-46	12
1103	T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. 2010 , 18, 2006-17	59
1102	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. 2010 , 10, 19-28	26
1101	Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. 2010 , 10, 735-48	8

1100	Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope. 2010 , 6, 34-40	1
1099	Subversion and coercion: the art of redirecting tumor immune surveillance. 2011 , 344, 25-39	3
1098	CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. 2010 , 70, 10170-81	40
1097	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 2010 , 95, 2022-30	66
1096	Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?. 2010 , 24, 109-27	1
1095	The role of tregs in glioma-mediated immunosuppression: potential target for intervention. 2010 , 21, 125-37	45
1094	FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. 2010 , 10, 631-40	16
1093	Interactions Between NK Cells and Regulatory T Cells. 2010 , 329-343	1
1092	OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. 2010 , 105, 63-98	93
1091	Regulatory T cells in cancer. 2010 , 107, 57-117	272
1090	Transforming growth factor-beta: recent advances on its role in immune tolerance. 2011 , 677, 303-38	95
1089	Targeting CCL11 in the treatment of ovarian cancer. 2010 , 14, 157-67	19
1088	Immune responses to malignancies. 2010 , 125, S272-83	129
1087	Developments in cancer immunotherapy. 2010 , 28, 51-6	10
1086	Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. 2010 , 8, 114	10
1085	Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. 2010 , 8, 79	31
1084	Immune infiltration in human cancer: prognostic significance and disease control. 2011 , 344, 1-24	126
1083	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. 2010 , 9, 617-29	20

1082	Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment. 2010 , 71, 36-44	5
1081	Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. 2010 , 41, 26-32	23
1080	Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. 2010 , 41, 1758-69	50
1079	Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. 2010 , 215, 153-62	30
1078	A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. 2010 , 10, 1055-61	38
1077	CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. 2010 , 17, 1381-5	105
1076	Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. 2010 , 287, 91-7	88
1075	Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. 2010 , 36, 458-67	208
1074	Lymphocytes in cancer development: polarization towards pro-tumor immunity. 2010 , 21, 3-10	164
1073	The chemokine system in cancer biology and therapy. 2010 , 21, 27-39	298
1072	Tumors as organs: complex tissues that interface with the entire organism. 2010 , 18, 884-901	827
1071	Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. 2010 , 46, 1514-9	33
1070	Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. 2010 , 36, 670-7	50
1069	Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. 2010 , 16, 1629-48	30
1068	Macrophage diversity enhances tumor progression and metastasis. 2010 , 141, 39-51	3150
1067	Dendritic-cell tumor vaccines. 2010 , 42, 3306-8	2
1066	Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. 2010 , 109, 744-52	106
1065	Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. 2010 , 22, 173-82	54

1064	Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma. 2010 , 135, 137-145	29
1063	Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. 2011 , 344, 129-48	68
1062	Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. 2010 , 24, 1118-23	66
1061	UK-PharmSci 2010 - The Science of Medicines. Abstracts from the UK-PharmSci Conference, 1-3 September 2010. 2010 , 62, 1201-516	4
1060	Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. 2010 , 40, 179-87	26
1059	Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview. 2011 , 677, 355-74	19
1058	Human FOXP3 and cancer. 2010 , 29, 4121-9	100
1057	Coupled for cross-presentation in tumor immunotherapy. 2010 , 2, 44ps40	4
1056	Immune regulation of cancer. 2010 , 28, 4531-8	318
1055	Forkhead Transcription Factors. 2010 ,	4
1054	Prognostic factors in follicular lymphoma. 2010 , 28, 2902-13	117
1053	Immunotherapy of Cancer. 2010 ,	1
1052	Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. 2010 , 107, 1-37	18
1051	STAT3: a target to enhance antitumor immune response. 2011 , 344, 41-59	84
1050	The Chemokine System in Experimental and Clinical Hematology. 2010 ,	5
1049	Natural Killer Cells. 2010 ,	3
1048	Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma. 2010 , 29, 78	12
1047	Photodynamic therapy for cancer and activation of immune response. 2010 ,	1

1046	Immune phenotype to predict cancer in renal transplant patients. 2010 , 5, 377-379	
1045	Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. 2010 , 173, 418-25	118
1044	Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. 2010 , 70, 9581-90	80
1043	Invasive aspergillosis promotes tumor growth and severity in a tumor-bearing mouse model. 2010 , 56, 771-6	2
1042	Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment. 2011 , 85, 397-408	144
1041	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. 2011 , 105, 93-103	813
1040	Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. 2011 , 3, 26	15
1039	The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. 2011 , 29, 419-25	14
1038	PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. 2011 , 71, 7463-70	330
1037	Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?. 2011 , 11, 441-5	22
1036	Th17 cells in cancer: help or hindrance?. 2011 , 32, 643-9	141
1035	Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. 2011 , 11, 855-73	111
1034	The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. 2011 , 18, 2263-71	60
1033	Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses. 2011 , 8, 93-103	4
1032	Experimental and Applied Immunotherapy. 2011 ,	
1031	Tumour-Induced Immune Suppression by Myeloid Cells. 2011 , 49-62	
1030	Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. 2011 , 3, 1235-51	39
1029	Tumor macrophages protective and pathogenic roles in cancer development. 2011 , 94, 309-28	14

1028	TH17 Cells in the Tumor Micro-environment. 2011 , 481-496	1
1027	Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. 2011 , 5, 242-55	25
1026	The immunoregulatory mechanisms of carcinoma for its survival and development. 2011 , 30, 12	41
1025	Suppression and Regulation of Immune Responses. 2011 ,	5
1024	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. 2011 , 13, 98-107	301
1023	Cancer Immunology and Immunotherapy. 2011 ,	1
1022	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. 2011 , 475, 226-30	801
1021	Bispecific Antibodies. 2011 ,	7
1020	Cancer immunotherapy comes of age. 2011 , 480, 480-9	2374
1019	Emerging Therapeutic Targets in Ovarian Cancer. 2011 ,	1
1018	Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. 2011 , 11, 1759-74	22
1017	Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. 2011 , 179, 37-45	178
1016	The imbalance of Th17/Treg in patients with uterine cervical cancer. 2011 , 412, 894-900	61
1015	Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. 2011 , 307, 165-73	22
1014	Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. 2011 , 47, 1883-9	40
1013	Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor. 2011 , 40, 383-99	8
1012	miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. 2011 , 1, 1637-1650	7
1011	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. 2011 , 118, 5021-30	34

1010	Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. 2011 , 11, 879-89	34
1009	Deciphering the role of Th17 cells in human disease. 2011 , 32, 603-11	173
1008	Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3(+) T lymphocytes in cervical cancer. 2011 , 110, 580-6	13
1007	Cancer immunotherapy--revisited. 2011 , 10, 591-600	282
1006	CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. 2011 , 29, 2649-52	9
1005	Maturation of human dendritic cells with <i>Saccharomyces cerevisiae</i> (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. 2011 , 29, 4992-9	17
1004	Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. 2011 , 25, 920-6	82
1003	Vitamin D-mediated immune regulation in multiple sclerosis. 2011 , 311, 23-31	37
1002	Protocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. 2011 , 13, R4	11
1001	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. 2011 , 13, R47	124
1000	The suppressive tumor microenvironment: a challenge in cancer immunotherapy. 2011 , 8, 635-41	124
999	Radiation enhances regulatory T cell representation. 2011 , 81, 1128-35	243
998	Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells. 2011 , 52, 990-8	3
997	Role of inflammation in oral carcinogenesis (Part I): Histological grading of malignancy using a binary system. 2011 , 2, 1225-1231	12
996	Circulating and tumor-infiltrating Foxp3+ regulatory T cell subset in Chinese patients with extranodal NK/T cell lymphoma. 2011 , 7, 1027-36	8
995	Chemokines: key players in cancer progression and metastasis. 2011 , 3, 1569-82	35
994	Relationship between RANTES and dendritic cells in ovarian cancer patients. 2011 , 3, 227-32	8
993	Cellular Immunotherapy for Malignant Brain Tumors. 2011 ,	

992	CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases. 2011 , 31, 231-7	20
991	Dual roles of immune cells and their factors in cancer development and progression. 2011 , 7, 651-8	433
990	Control of Adaptive Immunity by Vitamin D Receptor Agonists. 2011 , 1789-1809	4
989	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. 2011 , 2, 66	7
988	TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. 2011 , 6, e18833	49
987	WSX1 expression in tumors induces immune tolerance via suppression of effector immune cells. 2011 , 6, e19072	8
986	Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. 2011 , 6, e19495	148
985	In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF- β -secreting DCs is crucial for their enrichment and suppression in tumor immunity. 2011 , 6, e20282	17
984	SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer. 2011 , 6, e22047	49
983	NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment. 2011 , 6, e22845	12
982	Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. 2011 , 6, e24671	154
981	Tumor immune escape mechanisms that operate during metastasis. 2011 , 12, 1923-36	17
980	Multiple vaccinations: friend or foe. 2011 , 17, 379-96	12
979	Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF- β mRNA expression in peripheral blood mononuclear cells. 2011 , 34, 113-9	14
978	The potential role of functional inhibition of T regulatory cells by anti-TGF β antibody in photodynamic therapy of renal cancer. 2011 ,	
977	Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. 2011 , 23, 13-8	29
976	Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression. 2011 , 34, 516-23	23
975	The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells. 2011 , 34, 229-35	35

974	Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. 2011 , 21, 1241-7	14
973	Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells. 2011 , 2, 737-743	10
972	Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. 2011 , 11, 734-51	81
971	Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. 2011 , 117, 1555-64	16
970	T lymphocytes to IDO+ cells: check. 2011 , 117, 2082-3	4
969	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. 2011 , 118, 4853-62	130
968	CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells. 2011 , 118, 5141-51	62
967	The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. 2011 , 6, 824-33	209
966	Gastrointestinal Foxp3 expression in normal, inflammatory and neoplastic conditions. 2011 , 43, 465-71	2
965	Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. 2011 , 107, 1500-6	81
964	FOXP3 and survival in urinary bladder cancer. 2011 , 108, 1672-8	102
963	IL-23 gene therapy for mouse bladder tumour cell lines. 2011 , 108, 914-21	2
962	Immunohistochemical characterization of lymphocyte and myeloid cell infiltrates in spirocercosis-induced oesophageal nodules. 2011 , 33, 545-53	11
961	Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2. 2011 , 73, 222-33	17
960	Immunopathogenesis of lymphoma: focus on CCR4. 2011 , 102, 44-50	53
959	Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. 2011 , 102, 516-21	23
958	Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. 2011 , 102, 1272-80	58
957	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. 2011 , 102, 1972-6	8

956	Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma. 2011 , 164, 1052-60	18
955	Roles of the immune system in skin cancer. 2011 , 165, 953-65	114
954	Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. 2011 , 166, 154-63	35
953	The challenge of the microenvironment in B-cell lymphomas. 2011 , 58, 69-80	43
952	Impact of gene expression profiling in lymphoma diagnosis and prognosis. 2011 , 58, 106-27	11
951	In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype. 2011 , 59, 965-74	16
950	Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. 2011 , 133, 296-306	35
949	Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. 2011 , 20, 430-4	42
948	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. 2011 , 241, 104-18	185
947	Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma. 2011 , 40, 636-42	25
946	Effects of ultraviolet radiation exposure on FOXP3+ infiltration in cutaneous squamous cell carcinoma and basal cell carcinoma. 2011 , 27, 297-303	4
945	Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. 2011 , 66, 444-50	15
944	Chemotaxis in cancer. 2011 , 11, 573-87	628
943	Rethinking ovarian cancer: recommendations for improving outcomes. 2011 , 11, 719-25	893
942	The parallel lives of angiogenesis and immunosuppression: cancer and other tales. 2011 , 11, 702-11	301
941	Protective and pathogenic functions of macrophage subsets. 2011 , 11, 723-37	3114
940	Human FoxP3(+)/CD4(+) regulatory T cells: their knowns and unknowns. 2011 , 89, 346-51	142
939	Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. 2011 , 91, 598-608	92

938	Immunomodulatory effects of anti-angiogenic drugs. 2011 , 25, 899-905	55
937	Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. 2011 , 18, 407-18	19
936	Immunonutritional diet modulates natural killer cell activation and Th17 cell distribution in patients with gastric and esophageal cancer. 2011 , 27, 146-52	16
935	In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. 2011 , 365, 76-86	4
934	Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis. 2011 , 230, 33-41	23
933	Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. 2011 , 21, 131-8	51
932	Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients. 2011 , 47, 566-70	40
931	Donor Tregs suppress the good with the bad after allogeneic BMT. 2011 , 35, 1541-2	1
930	FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. 2011 , 120, 296-9	15
929	Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. 2011 , 122, 307-12	24
928	Identification and manipulation of tumor associated macrophages in human cancers. 2011 , 9, 216	323
927	Cell communication networks in cancer invasion. 2011 , 23, 621-9	61
926	Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model. 2011 , 271, 360-4	9
925	Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. 2011 , 138, 85-96	58
924	Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. 2011 , 139, 350-9	35
923	Natural innate and adaptive immunity to cancer. 2011 , 29, 235-71	1353
922	Targeting regulatory T cells in cancer. 2011 , 71, 6915-20	158
921	Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. 2011 , 18, 2585-93	79

920	Vaccine-based clinical trials in ovarian cancer. 2011 , 10, 775-84	12
919	IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma. 2011 , 31, 1084-94	38
918	Innate immune cells in breast cancer--from villains to heroes?. 2011 , 16, 189-203	23
917	Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. 2011 , 125, 65-72	105
916	An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. 2011 , 127, 99-108	129
915	CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. 2011 , 130, 645-55	214
914	Genomics of the NF- κ B signaling pathway: hypothesized role in ovarian cancer. 2011 , 22, 785-801	22
913	Myeloid cell diversification and complexity: an old concept with new turns in oncology. 2011 , 30, 27-43	34
912	Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. 2011 , 30, 141-51	41
911	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. 2011 , 60, 197-206	47
910	2011: the immune hallmarks of cancer. 2011 , 60, 319-26	260
909	Changes in immunocompetent cells after interstitial laser thermotherapy of breast cancer. 2011 , 60, 847-56	9
908	Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. 2011 , 60, 1109-18	36
907	Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. 2011 , 60, 1405-18	132
906	Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. 2011 , 60, 909-18	247
905	Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. 2011 , 60, 1789-800	32
904	Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. 2011 , 60, 1509-27	42
903	Regulatory T cells in lung transplantation--an emerging concept. 2011 , 33, 117-27	19

902	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. 2011 , 33, 335-40	82
901	How tumors might withstand T-cell attack. 2011 , 68, 2433-42	17
900	Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist. 2011 , 17, 80-90	8
899	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. 2011 , 50, 235-47	24
898	The mechanisms of cancer immunoescape and development of overcoming strategies. 2011 , 93, 294-300	88
897	Cancer-immune equilibrium: questions unanswered. 2011 , 4, 209-17	25
896	The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN. 2011 , 6, 147-54	14
895	Correlation between CD4+CD25+Treg cells and CCR4 in nasopharyngeal carcinoma. 2011 , 8, 106-113	2
894	An immunologic portrait of cancer. 2011 , 9, 146	77
893	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. 2011 , 9, 204	412
892	Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. 2011 , 9, 217	23
891	T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3. 2011 , 4, 48	5
890	CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. 2011 , 12, 77	40
889	In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. 2011 , 224, 389-400	163
888	Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor- β . 2011 , 104, 571-7	23
887	The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. 2011 , 104, 728-33	37
886	Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. 2011 , 41, 3564-73	27
885	Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. 2011 , 41, 3615-26	32

884	Increased frequencies of CD4+ CD25+ FOXP3+ regulatory T cells in human nasal inverted papilloma. 2011 , 33, 1005-12	7
883	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. 2011 , 117, 2163-9	42
882	An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. 2011 , 128, 897-907	60
881	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. 2011 , 129, 507-12	110
880	CD8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. 2011 , 129, 636-47	20
879	Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. 2011 , 129, 1990-2001	37
878	CD103 is a hallmark of tumor-infiltrating regulatory T cells. 2011 , 129, 2417-26	70
877	Role of CD4+ CD25+ regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. 2011 , 294, 781-8	42
876	Tetraspanins in the immune response against cancer. 2011 , 138, 129-36	33
875	T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF- β cytokine. 2011 , 35, 123-34	91
874	Immunosurveillance in human non-viral cancers. 2011 , 23, 272-8	37
873	Pulling the trigger on the tumor's bodyguards: what puts Tregs out of action?. 2011 , 3, 693-5	
872	Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. 2011 , 3, 805-7	3
871	Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth. 2011 , 3, 949-69	22
870	Immunity and immune suppression in human ovarian cancer. 2011 , 3, 539-56	83
869	Targeting regulatory T cells for anticancer therapy. 2011 , 11, 480-5	6
868	Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. 2011 , 3, 77-96	23
867	The tumor microenvironment: part 1. 2011 , 3, 1367-84	18

866	Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. 2011 , 13, 3-13	84
865	Lenalidomide in the treatment of chronic lymphocytic leukemia. 2011 , 20, 273-86	7
864	Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. 2011 , 115, 505-11	81
863	Induction of regulatory T Cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of acquired peripheral tolerance. 2011 , 18, 2234-9	21
862	The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). 2011 , 18, 5217-23	58
861	Therapeutic targeting of B7-H1 in breast cancer. 2011 , 15, 1211-25	34
860	Immune microenvironments in solid tumors: new targets for therapy. 2011 , 25, 2559-72	235
859	Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. 2011 , 365, 2067-77	544
858	A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. 2011 , 17, 7164-73	95
857	Immunotherapy for ovarian cancer: what's next?. 2011 , 29, 925-33	95
856	Down-regulation of Treg cells and up-regulation of TH1/TH2 cytokine ratio were induced by polysaccharide from Radix Glycyrrhizae in H22 hepatocarcinoma bearing mice. 2011 , 16, 8343-52	30
855	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. 2011 , 71, 5522-5534	171
854	Multiple Myeloma. 2011 ,	2
853	Regulatory T cells: customizing for the clinic. 2011 , 3, 83ps19	29
852	Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. 2011 , 29, 316-23	51
851	Human TH17 cells are long-lived effector memory cells. 2011 , 3, 104ra100	195
850	Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?. 2011 , 17, 4214-24	29
849	Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond. 2011 , 30, 138-49	13

848	Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. 2011 , 3, 3114-42	53
847	Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. 2011 , 2011, 734036	28
846	Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. 2011 , 71, 1263-71	773
845	Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. 2012 , 40, 840-50	22
844	Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. 2011 , 10, 396-405	147
843	Epigenetic quantification of tumor-infiltrating T-lymphocytes. 2011 , 6, 236-46	71
842	Early effects of low dose C ion or x-ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer. 2011 , 9, 356-68	8
841	Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. 2011 , 12, 367-77	17
840	Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. 2011 , 12, 357-66	8
839	Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3+ cells. 2011 , 186, 6788-97	56
838	Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. 2011 , 187, 118-25	62
837	Antigen localization controls T cell-mediated tumor immunity. 2011 , 187, 1281-8	39
836	IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. 2011 , 186, 4388-95	198
835	Antigen-specific TGF- β -induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity. 2011 , 187, 1745-53	44
834	Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. 2011 , 186, 6905-13	179
833	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. 2011 , 10, 743-53	15
832	TNM staging in colorectal cancer: T is for T cell and M is for memory. 2011 , 29, 601-3	72
831	Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. 2011 , 208, 469-78	454

830	Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. 2011 , 3, 2904-54	10
829	The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. 2011 , 2011, 182413	7
828	Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. 2011 , 2011, 269519	29
827	Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. 2011 , 30, 71-86	7
826	Immune therapy for ovarian cancer: promise and pitfalls. 2011 , 30, 102-19	19
825	CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. 2011 , 19, 760-7	89
824	Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E ₂ cooperation. 2011 , 11, 1203-14	23
823	Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. 2011 , 71, 6143-52	82
822	Regulatory T cells in colorectal cancer: from biology to prognostic relevance. 2011 , 3, 1708-31	14
821	The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. 2011 , 2011, 430394	62
820	Tumor evasion from T cell surveillance. 2011 , 2011, 918471	105
819	Regulatory T cells in gastrointestinal tumors. 2011 , 5, 489-501	24
818	TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. 2011 , 186, 1963-9	90
817	Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. 2011 , 98, E25-31	54
816	Peritoneal immune system in patients with advance epithelial ovarian cancer. 2011 , 30, 87-101	11
815	Antigen-presenting cell (APC) subsets in ovarian cancer. 2011 , 30, 120-6	27
814	From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. 2011 , 2011, 439053	115
813	Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. 2012 , 18, 5212-23	80

812	Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. 2012 , 11, 2451-61	50
811	Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. 2012 , 2012, 756353	21
810	Mechanisms and Control of Regulatory T Cells in Cancer. 2012 , 195-216	1
809	Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times. 2012 , 120, 164-8	3
808	Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. 2012 , 72, 5240-9	193
807	T cells in gastric cancer: friends or foes. 2012 , 2012, 690571	30
806	Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. 2012 , 2012, 753407	24
805	The role of bacterial lipopolysaccharides as immune modulator in vaccine and drug development. 2012 , 12, 221-35	18
804	Regulatory T cells in radiotherapeutic responses. 2012 , 2, 90	58
803	Ovarian cancer stroma: pathophysiology and the roles in cancer development. 2012 , 4, 701-24	16
802	Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. 2012 , 3, 103	5
801	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. 2012 , 23, 435-41	42
800	Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo. 2012 , 11, 1183-92	12
799	T regulatory cell therapy in transplantation: stability, localization and functional specialization. 2012 , 17, 343-8	19
798	Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. 2012 , 61, 1180-91	57
797	The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. 2012 , 18, 3022-9	331
796	Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. 2012 , 18, 1925-35	70
795	CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. 2012 , 72, 4351-60	100

794	IL-13 receptor-directed cancer vaccines and immunotherapy. 2012 , 4, 443-51	13
793	Tumor-derived chemokine CCL5 enhances TGF- β -mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. 2012 , 72, 1092-102	144
792	Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. 2012 , 72, 2089-99	72
791	Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. 2012 , 189, 5171-7	49
790	Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. 2012 , 18, 850-7	58
789	Chemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseases. 2012 , 4, 9-12	0
788	Immunotherapy in ovarian cancer. 2012 , 8, 1179-91	36
787	Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer. 2021 , 1	
786	Immune System Effects on Breast Cancer. 2021 , 14, 279-292	0
785	Ovarian Cancer Immunotherapy and Personalized Medicine. 2021 , 22,	14
784	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. 2021 , 125, 717-724	0
783	Anti-proliferative, antioxidant effects of methanol extract of Calotropis procera leaf on lung cancer cells (H1299) and its ameliorative effect on expression of CD146 on blood cells. 2021 , 7,	0
782	Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proof-of-concept study. 2021 , 86, e13469	1
781	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. 2021 , 12, 690112	6
780	Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor. 2021 ,	1
779	Comparing immunotherapies to other frequently used treatments of gastric cancer. 2021 , 14, 1221-1232	0
778	PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity. 2021 , 118,	2
777	A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients. 2021 , 11, 698856	3

776	Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. 2021 , 9, 59	7
775	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. 2021 , 9,	11
774	Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. 2021 , 81, 1128-1144	3
773	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. 2021 , 12, 4091	13
772	Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy. 2021 , 69, 398-414	1
771	Gold nanorods-mediated efficient synergistic immunotherapy for detection and inhibition of postoperative tumor recurrence. 2021 , 11, 1978-1992	5
770	The Complement System in Ovarian Cancer: An Underexplored Old Path. 2021 , 13,	0
769	Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. 2021 , 113, 20-27	3
768	Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. 2021 , 11, 682075	1
767	Inflammation and tumor progression: signaling pathways and targeted intervention. 2021 , 6, 263	107
766	Instruction of Immunometabolism by Adipose Tissue: Implications for Cancer Progression. 2021 , 13,	2
765	Evaluating Anticancer and Immunomodulatory Effects of (Arthrospira) and Gamma-Tocotrienol Supplementation in a Syngeneic Mouse Model of Breast Cancer. 2021 , 13,	2
764	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. 2021 , 27, 5536-5545	3
763	Heterogeneous Myeloid Cells in Tumors. 2021 , 13,	2
762	Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. 2021 , 14, 4217-4228	3
761	A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. 2021 , 21, 901	5
760	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. 2021 ,	5
759	Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. 2021 , 9, 714718	

758	Prospects for Manipulation of Mesenchymal Stem Cells in Tumor Therapy: Anti-Angiogenesis Property on the Spotlight. 2021 , 14, 351-365	1
757	The antioncogenic effect of Beclin-1 and FOXP3 is associated with SKP2 expression in gastric adenocarcinoma. 2021 , 100, e26951	0
756	IFN β signaling integrity in colorectal cancer immunity and immunotherapy. 2021 ,	4
755	Biological correlates before esophageal cancer screening and after diagnosis. 2021 , 11, 17015	2
754	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. 2021 , 23, 83	3
753	Immune Privilege of Heart Valves. 2021 , 12, 731361	1
752	Chemokines and the extracellular matrix: Set of targets for tumor development and treatment. 2021 , 144, 155548	5
751	Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. 2021 , 11, 739191	1
750	Strategies to Improve the Antitumor Effect of T Cell Immunotherapy for Clinical Application. 2021 , 22,	5
749	The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer. 2021 , 13,	1
748	Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. 2021 , 77, 144-166	7
747	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. 2021 , 10,	2
746	Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer. 2021 , 513, 63-74	2
745	Dual targeting of CTLA-4 and CD47 on T cells promotes immunity against solid tumors. 2021 , 13,	8
744	Increased CD3, CD8, or FoxP3 T Lymphocyte Infiltrations Are Associated with the Pathogenesis of Colorectal Cancer but Not with the Overall Survival of Patients. 2021 , 10,	1
743	Reactive oxygen species in cancer: Current findings and future directions. 2021 , 112, 3945-3952	24
742	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. 2021 , 13,	4
741	MK-6, a novel not-IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance. 2021 , 112, 4478-4489	1

740	Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. 2021 ,	9
739	Identification of metabolism-associated molecular subtype in ovarian cancer. 2021 , 25, 9617-9626	1
738	Surgical Trauma-induced CCL2 Upregulation Mediates Lung Cancer Progression by Promoting Treg Recruitment in Mice and Patients. 2021 , 1-12	0
737	Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer. 2021 , 39, 3651-3655	4
736	Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. 2021 , 29, 2723-2736	18
735	Leveraging the Treg-intrinsic CTLA4-PKC β signaling pathway for cancer immunotherapy. 2021 , 9,	1
734	Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. 2021 , 11, 705614	5
733	Combination strategies to maximize the benefits of cancer immunotherapy. 2021 , 14, 156	19
732	Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy. 2021 , 22,	8
731	Targeting immunosuppression by TGF- β for cancer immunotherapy. 2021 , 192, 114697	4
730	The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. 2021 , 284, 119132	4
729	Advance of nano anticancer therapies targeted on tumor-associated macrophages. 2021 , 446, 214126	2
728	Prolactin enhances T regulatory cell promotion of breast cancer through the long form prolactin receptor. 2021 , 14, 101195	0
727	Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer. 2021 , 14, 101217	0
726	Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy. 2022 , 127-151	
725	Molecular oncology in gynecologic cancer. 2022 , 606-617.e3	
724	The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?. 2021 , 11, 146-161	1
723	Driving Immune Responses in the Ovarian Tumor Microenvironment. 2020 , 10, 604084	6

722	Moonlighting Proteins Are Important Players in Cancer Immunology. 2020 , 11, 613069	7
721	Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients. 2021 , 70, 1877-1891	3
720	Cellular Indoctrination: How the Tumor Microenvironment Reeducates Macrophages Towards Nefarious Ends. 2021 ,	
719	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. 2021 , 13, 17588359211039899	4
718	Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity. 2021 , 4, 78	3
717	Sono/Photodynamic Nanomedicine-Elicited Cancer Immunotherapy. 2021 , 31, 2008061	22
716	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. 2021 , 10, 709-717	7
715	Immune Escape. 2005 , 43-81	6
714	Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. 2005 , 293, 287-302	67
713	Cancer-Induced Signaling Defects in Antitumor T Cells. 2008 , 69-100	3
712	T cell tolerance to tumors and cancer immunotherapy. 2007 , 601, 357-68	10
711	Tumor-Stromal Interactions in Invasion and Metastases. 2010 , 535-563	2
710	CD4+Foxp3+Regulatory T Cells in Immune Tolerance. 2008 , 155-198	1
709	An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions. 2020 , 2097, 139-171	2
708	Immune Effector Cells in the Tumor Microenvironment: Their Role in Regulation of Tumor Progression. 2008 , 1-33	2
707	The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. 2009 , 665, 47-59	31
706	Immune Signatures Associated with the Cancer Bearing State. 2011 , 169-186	1
705	The Role of NKT Cells in the Immune Regulation of Neoplastic Disease. 2012 , 7-21	1

704	Antibodies as Cancer Immunotherapy. 2013 , 335-376	2
703	Generation and identification of tumor-evoked regulatory B cells. 2014 , 1190, 271-89	7
702	Characterization of regulatory T cells in tumor suppressive microenvironments. 2010 , 651, 31-48	1
701	Gene therapy to improve migration of T cells to the tumor site. 2010 , 651, 103-18	8
700	Natural Killer Cells for Cancer Immunotherapy. 2011 , 85-105	3
699	Depletion of human regulatory T cells. 2011 , 707, 219-31	15
698	miRNAs in human cancer. 2012 , 822, 295-306	48
697	Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. 2020 , 1224, 35-51	4
696	CCL22 Signaling in the Tumor Environment. 2020 , 1231, 79-96	12
695	Hyaluronan in the Tumor Microenvironment. 2020 , 1245, 67-83	16
694	Overview of Basic Immunology and Clinical Application. 2020 , 1244, 1-36	6
693	Regulatory T Cells in the Tumor Microenvironment. 2020 , 1273, 105-134	7
692	Serotonin modulation of macrophage polarization: inflammation and beyond. 2014 , 824, 89-115	35
691	Infectious Diseases in Cancer Patients: An Overview. 2015 , 295-311	2
690	Immunology and immunotherapeutic approaches in multiple myeloma. 2011 , 183, 97-109	2
689	Basic concepts of inflammation and its role in carcinogenesis. 2011 , 185, 1-34	10
688	Trifunctional Triomab [®] Antibodies for Cancer Therapy. 2011 , 289-312	7
687	Effects of Metronomic Chemotherapy on Immunity. 2014 , 39-51	1

686	Prognostic Value of Innate and Adaptive Immunity in Cancers. 2015 , 275-284	1
685	Regulatory T Cells and Th17 Cells in Cancer Microenvironment. 2015 , 77-91	1
684	Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer. 2015 , 93-119	4
683	Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses. 2014 , 207-232	2
682	Models of inflammatory processes in cancer. 2006 , 83-102	3
681	Macrophages. 2016 , 169-178	1
680	Immunophenotype. 2017 , 67-81	1
679	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. 2013 , 1-28	2
678	Glioblastoma Microvesicles Transport RNA and Proteins, Promoting Tumor Growth. 2014 , 101-112	1
677	Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery. 2020 , 1248, 227-250	1
676	Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. 2020 , 146, 3123-3135	4
675	Tumor-Associated Macrophages in Cancer Growth and Progression. 2007 , 289-307	1
674	Cancer Immunology. 2014 , 78-97.e5	2
673	Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?. 2017 , 215, 55-61	4
672	Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer. 2013 , 15, 461-5	17
671	Macrophages as regulators of tumour immunity and immunotherapy. 2019 , 19, 369-382	621
670	Immune crosstalk in cancer progression and metastatic spread: a complex conversation. 2020 , 20, 483-497	120
669	Profiles of immune cell infiltration in head and neck squamous carcinoma. 2020 , 40,	14

668	p110PI3K as a therapeutic target of solid tumours. 2020 , 134, 1377-1397	7
667	Delicate balances in cancer chemotherapy: Modeling immune recruitment and emergence of systemic drug resistance.	1
666	Bcl6 Preserves the Suppressive Function of Regulatory T Cells during Tumorigenesis.	1
665	Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. 2020 , 111, 23-35	16
664	CD20 tumor-infiltrating immune cells and CD204 M2 macrophages are associated with prognosis in thymic carcinoma. 2020 , 111, 1921-1932	11
663	Trials with impact on clinical management: first line. 2009 , 19 Suppl 2, S55-62	16
662	Regulatory T Cells and Human Disease. 2020 , 38, 541-566	191
661	Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. 2021 , 81, 968-985	7
660	Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFN γ -Dependent Tumor Vessel Regression. 2021 , 81, 3092-3104	7
659	Cancer-Associated Fibroblasts Affect Intratumoral CD8 and FoxP3 T Cells Via IL6 in the Tumor Microenvironment. 2018 , 24, 4820-4833	128
658	Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. 2019 , 4,	57
657	IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. 2018 , 3,	24
656	microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance. 2019 , 129, 1257-1271	26
655	A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. 2020 , 130, 1405-1416	32
654	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. 2020 , 130, 2712-2726	45
653	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. 2006 , 116, 1935-45	531
652	MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. 2007 , 117, 1902-13	158
651	Tregs and rethinking cancer immunotherapy. 2007 , 117, 1167-74	416

650	Harnessing the immune system to treat cancer. 2007 , 117, 1130-6	88
649	Tumor emergence is sensed by self-specific CD44 ^{hi} memory Tregs that create a dominant tolerogenic environment for tumors in mice. 2009 , 119, 2648-62	84
648	Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. 2009 , 119, 2231-44	158
647	Identification of heme oxygenase-1-specific regulatory CD8 ⁺ T cells in cancer patients. 2009 , 119, 2245-56	58
646	Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. 2009 , 119, 3311-21	155
645	An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. 2010 , 120, 3234-41	73
644	Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. 2010 , 120, 4558-68	133
643	Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. 2011 , 121, 3024-8	81
642	Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. 2013 , 123, 1216-28	82
641	Type III TGF- β receptor downregulation generates an immunotolerant tumor microenvironment. 2013 , 123, 3925-40	74
640	Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. 2014 , 124, 2425-40	145
639	CD4 ⁺ follicular helper T cell infiltration predicts breast cancer survival. 2013 , 123, 2873-92	554
638	CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. 2014 , 124, 2977-87	96
637	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. 2015 , 125, 3365-76	351
636	A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. 2017 , 127, 801-813	49
635	T regulatory cell chemokine production mediates pathogenic T cell attraction and suppression. 2016 , 126, 1039-51	34
634	The impact of hypoxia on tumor-associated macrophages. 2016 , 126, 3672-3679	250
633	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. 2018 , 128, 2487-2499	48

632	Spontaneous endometrial hyperplasia in the uteri of IL-2 receptor beta-chain transgenic mice. 2009 , 55, 273-7	1
631	Therapeutic strategies for targeting the ovarian tumor stroma. 2014 , 2, 194-200	14
630	Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. 2009 , 4, e4942	286
629	Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. 2011 , 6, e17515	34
628	Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice. 2011 , 6, e25424	37
627	Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. 2012 , 7, e30229	27
626	Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. 2012 , 7, e31524	209
625	Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. 2012 , 7, e31962	38
624	High-anxious individuals show increased chronic stress burden, decreased protective immunity, and increased cancer progression in a mouse model of squamous cell carcinoma. 2012 , 7, e33069	52
623	Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. 2012 , 7, e41746	25
622	Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. 2012 , 7, e44455	25
621	Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. 2012 , 7, e46342	65
620	Immunologic targeting of FOXP3 in inflammatory breast cancer cells. 2013 , 8, e53150	12
619	Inherited variants in regulatory T cell genes and outcome of ovarian cancer. 2013 , 8, e53903	19
618	Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. 2013 , 8, e69631	16
617	CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. 2013 , 8, e74430	34
616	Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer. 2013 , 8, e76379	51
615	Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. 2013 , 8, e82406	18

614	Fully human antagonistic antibodies against CCR4 potentially inhibit cell signaling and chemotaxis. 2014, 9, e103776	20
613	CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. 2014, 9, e103975	41
612	Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. 2014, 9, e111586	10
611	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. 2015, 10, e0131934	10
610	The Immune Landscapes of Polypoid and Nonpolypoid Precancerous Colorectal Lesions. 2016, 11, e0159373	11
609	Global Regulatory T-Cell Research from 2000 to 2015: A Bibliometric Analysis. 2016, 11, e0162099	25
608	Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. 2017, 12, e0175712	23
607	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. 2017, 12, e0176181	49
606	Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity. 2018, 41, 653-664	7
605	Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis. 2015, 2,	13
604	Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?. 2016, 33, 237-246	1
603	Regulatory T Cells in Gynecologic Cancer. 2018, 6,	12
602	The immune system in the pathogenesis of ovarian cancer. 2013, 33, 137-64	41
601	Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. 2010, 30, 435-47	69
600	Clinical Applications of Regulatory T cells in Adoptive Cell Therapies.. 2018, 4, 405-429	3
599	A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer. 2020, 12, 4879-4895	20
598	Chemokines and cellular plasticity of ovarian cancer stem cells. 2015, 2, 615-6	8
597	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. 2016, 7, 47252-47264	65

596	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. 2016 , 7, 69097-69110	4
595	Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. 2016 , 7, 52849-52861	24
594	Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. 2016 , 7, 59087-59097	50
593	Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness. 2016 , 7, 55473-55490	15
592	Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity. 2016 , 7, 60383-60394	19
591	Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. 2016 , 7, 75763-75773	76
590	Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. 2016 , 7, 85624-85640	36
589	Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. 2017 , 8, 5219-5232	11
588	Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. 2017 , 8, 19803-19813	22
587	CCR4 is a determinant of melanoma brain metastasis. 2017 , 8, 31079-31091	47
586	CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. 2010 , 1, 329-38	54
585	Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. 2017 , 8, 54173-54186	25
584	Oroxlylin A inhibits the generation of Tregs in non-small cell lung cancer. 2017 , 8, 49395-49408	7
583	Tumor-infiltrating FoxP3 Tregs predict favorable outcome in colorectal cancer patients: A meta-analysis. 2017 , 8, 75361-75371	28
582	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. 2017 , 8, 71709-71724	16
581	Checkpoint and PARP inhibitors, for whom and when. 2017 , 8, 95036-95037	7
580	Epigenetic changes found in uterine decidual and placental tissues can also be found in the breast cancer microenvironment of the same unique patient: description and potential interpretations. 2018 , 9, 6028-6041	4
579	Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer. 2018 , 9, 2515-2526	5

578	Aberrant frequency of TNFR2 Treg and related cytokines in patients with CIN and cervical cancer. 2018 , 9, 5073-5083	16
577	S100A9 MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of. 2018 , 9, 7631-7643	17
576	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. 2020 , 11, 2669-2683	2
575	Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. 2015 , 6, 4190-201	38
574	Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. 2015 , 6, 11310-26	37
573	Heme oxygenase-1 promotes tumor progression and metastasis of colorectal carcinoma cells by inhibiting antitumor immunity. 2015 , 6, 19792-806	13
572	The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis. 2015 , 6, 19671-84	10
571	Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells. 2015 , 6, 32138-53	25
570	Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. 2015 , 6, 24649-59	10
569	Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor EDAB2IP signals. 2015 , 6, 44346-59	14
568	CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction. 2016 , 7, 15525-38	14
567	Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. 2016 , 7, 22174-85	30
566	Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. 2016 , 7, 37714-37727	26
565	Targeting tumor-associated macrophages to combat pancreatic cancer. 2016 , 7, 50735-50754	63
564	Impact of autoimmune diseases on outcome of patients with early breast cancer. 2016 , 7, 51184-51192	8
563	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.. 2019 , 2, 744-761	1
562	Cell-mediated immune resistance in cancer.. 2020 , 3, 232-251	6
561	Predictors of response and resistance to checkpoint inhibitors in solid tumors. 2017 , 5, 468	7

560	Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. 2019 , 7, 645	13
559	Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. 2011 , 3, 25-38	39
558	Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells. 2019 , 12, 11033-11044	6
557	Histone Deacetylase Inhibitors in Tumor Immunotherapy. 2019 , 26, 2990-3008	18
556	Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review. 2020 , 27, 4673-4698	8
555	Immunotherapy of human cancers using gene modified T lymphocytes. 2009 , 9, 396-408	25
554	Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy. 2019 , 19, 1464-1483	1
553	Small-Molecule CSF1R Inhibitors as Anticancer Agents. 2020 , 27, 3944-3966	17
552	Current perspectives in prostate cancer vaccines. 2009 , 9, 1052-7	2
551	Antigen-specific immunotherapy for ovarian cancer. 2012 , 136-154	1
550	The immunomodulating roles of glycoproteins in epithelial ovarian cancer. 2012 , 4, 631-50	1
549	Regulatory T Cells in the Human Immune System. 2010 , 53, 737	1
548	Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. 2020 , 13,	7
547	The Many Faces of CD4 T Cells: Immunological and Structural Characteristics. 2020 , 22,	14
546	Cancer/testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model. 2013 , 21, 193-200	7
545	Role of vaccine therapy in cancer: biology and practice. 2007 , 14, 238-45	8
544	Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. 2008 , 14, 5797-809	17
543	Immunotherapy and immunoescape in colorectal cancer. 2007 , 13, 5822-31	32

542	Immunological milieu in the peritoneal cavity at laparotomy for gastric cancer. 2012 , 18, 1470-8	7
541	Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. 2012 , 18, 2938-47	30
540	Prognostic value of innate and adaptive immunity in colorectal cancer. 2013 , 19, 174-84	46
539	Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors. 2020 , 26, 4656-4668	3
538	Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma. 2017 , 14, 7957-7964	11
537	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. 2015 , 27, 376-91	11
536	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. 2015 , 4, 728-42	40
535	Melanoma: oncogenic drivers and the immune system. 2015 , 3, 265	15
534	Immune Checkpoint Blockers and Ovarian Cancer. 2017 , 38, 182-189	3
533	Cancer: Tumor Iron Metabolism, Mitochondrial Dysfunction and Tumor Immunosuppression; A Tight Partnership Was Warburg Correct? 2012 , 03, 278-311	19
532	The Research of Treg Cells: Progress and Challenge. 2015 , 05, 150-165	1
531	Immune cell interplay in colorectal cancer prognosis. 2015 , 7, 221-32	24
530	Aiming to immune elimination of ovarian cancer stem cells. 2013 , 5, 149-62	4
529	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. 2016 , 7, 242-55	10
528	The Roles of CD4+ T Cells in Tumor Immunity. 2011 , 2011, 1-6	26
527	Mechanism of T cell exhaustion in a chronic environment. 2011 , 44, 217-31	40
526	Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. 2012 , 67, 483-8	40
525	Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, icatibant, imiquimod peritoneal lavage, and plerixafor. 2012 , 1, 2	2

524	Tumor-derived transforming growth factor- β s critical for tumor progression and evasion from immune surveillance. 2014 , 15, 5181-6	32
523	Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. 2013 , 10, 123-30	46
522	The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer. 2018 , 7,	31
521	Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer. 2019 , 7, e7804	10
520	Immunological Tolerance. 2021 ,	1
519	Dormancy in the Tumor Microenvironment. 2021 , 1329, 35-49	1
518	Tumormicroenvironment. 2021 , 1-7	
517	Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer. 2021 , 10,	2
516	Estrogens and the Schrödinger's Cat in the Ovarian Tumor Microenvironment. 2021 , 13,	1
515	Immunoregulation by type I interferons in the peritoneal cavity. 2021 ,	
514	Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer. 2021 , 13, 23210-23232	2
513	Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. 2021 , 13,	5
512	Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma. 2021 , 100, e27473	2
511	Hodgkin Lymphoma: A Special Microenvironment. 2021 , 10,	1
510	ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. 2021 , 12, 969	4
509	Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment. 2021 , 10,	1
508	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. 2021 , 12, 5866	6
507	Immune cells of the epithelial ovarian cancer microenvironment. 2021 , 67-78	

506	Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. 2021 , 9, 72	8
505	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. 2021 , 9,	4
504	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. 2021 , 9, 738373	1
503	Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. 2021 , 23, 95	1
502	The tumor immune microenvironments of HPV and HPV head and neck cancers.. 2021 , e1539	1
501	Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. 2021 , 27, 6775-6793	0
500	The TNF- α /TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. 2021 , 9, 725473	3
499	A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. 2021 , 240, 137-148	2
498	Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. 2021 , 179, 114003	2
497	Bedeutung der Expression des T-reg Markers FOXP3 in Pankreasadenocarcinomzelllinien in Hinblick auf eine immunmodulatorische Wirkung auf naive T-Zellen. 2006 , 109-110	
496	Tumor Vaccines for Breast Cancer. 2007 , 297-312	
495	The Tumor Microenvironment as a Model for Tissue-Specific Rejection. 2008 , 139-155	
494	Cancer-Specific Vaccines. 2008 , 649-669	
493	Perturbations of TGF- β Signaling in Leukocytes as Drivers of Leukemogenesis and Epithelial Tumorigenesis. 2008 , 181-202	
492	Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?. 2008 , 293-306	
491	Tumor Suppressor Functions of TGF- β in T Cells. 2008 , 353-366	
490	T-cell Unresponsiveness in Renal Cell Carcinoma Patients. 2008 , 115-130	
489	TGF- β at the Crossroads Between Inflammation, Suppression and Cancer. 2008 , 553-570	

488 Cancer and the Cellular Immune Response. **2008**, 635-647

487 Regulatory T Cells and Tumour Immunotherapy. **2008**, 379-392

486 Development of Vaccine Therapy for Pancreas Cancer. **2008**, 683-704

485 Cancer Immunology. **2008**, 77-93

1

484 Cellular Immunology. **2008**, 137-179

483 Immunomics of Immune Rejection. **2009**, 87-105

482 Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. **2009**, 367-403

481 Immune Recognition of Breast Cancer. **2009**, 589-594

480 Immune Cells and the Tumor Microenvironment. **2009**, 818-829

479 Functional Defects of Dendritic Cells in Cancer. **2009**, 57-75

478 New Strategies to Improve Tumor Cell Vaccine Therapy. **2009**, 117-131

477 Cellular immunotherapy (CI), where have we been and where are we going?. **2009**, 505-526

476 Vaccine-Primed Lymph Node Cells in the Adoptive Immunotherapy of Cancer: Presence of Host Immune Suppression Induced by Established Cancer. **2009**, 425-432

475 Role of IL12 Family in Regulation of Antitumor Immune Response. **2009**, 3-18

474 Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention. **2009**, 263-279

473 Modification of Dendritic Cells to Enhance Cancer Vaccine Potency. **2009**, 133-157

472 Immune-evasion of melanoma. **2009**, 24, 159-163

471 Dendritic Cells. **2010**, 807-854

470 The Prognostic Significance of Tumor-Infiltrating Lymphocytes. **2010**, 385-407

469 Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. **2010**, 305-319

468 Treatment of Immunomediated Diseases by Vitamin D Analogs. **2010**, 1025-1041

467 Tumor Microenvironment. **2010**, 27-69

1

466 Current Chemotherapy of Ovarian Cancer. **2010**, 7-25

465 The Micro- and Nanoscale Architecture of the Immunological Synapse. 323

464 Ovarian Cancer Immunology and Immunotherapy. **2011**, 203-221

463 The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. **2011**, 211-228

1

462 Targeting Inflammatory Pathways in Epithelial Ovarian Cancer. **2011**, 133-164

461 T Regulatory Cells and Cancer Immunotherapy. **2011**, 207-228

460 Melanoma Stem Cells. **2011**, 255-279

459 The Biology of Skin Cancer Invasion and Metastasis. **2011**, 1-11

458 Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer. **2011**, 45, 53

2

457 Immunomodulatory Functions of Cancer Stem Cells. **2012**, 301-332

456 Regulatory T Cells in Cancer. **2012**, 147-173

455 Relationship Between Th17 and Regulatory T Cells in the Tumor Environment. **2012**, 175-193

454 Modulating the Tumor Microenvironment. **2012**, 353-369

453 Influence of Different Stem Cell Mobilization Strategies on Graft Composition and Outcome of Autologous or Allogeneic Transplantation. **2012**, 165-200

452 Basic Principles of Immunology in Urology. **2012**, 495-529.e5

451 Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules. **2013**, 399-424

450 Managing Regulatory T Cells to Improve Cancer Immunotherapy. **2013**, 281-314

449 Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. **2013**, 71-108

448 Strategies for the Induction of Tolerance with Monoclonal Antibodies. **2013**, 279-295

447 Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. **2013**, 373-399

446 Dendritic Cells for Cancer Immunotherapy. **2013**, 251-270

445 Therapeutic Targeting Regulatory T Cells in Tumor. **2013**, 585-602

444 Development of Antitumor Cellular Immunity. **2013**, 107-133

443 Tumor Infiltration by Immune Cells: Pathologic Evaluation and a Clinical Significance. **2013**, 39-82 1

442 Approaches to Immunologic Monitoring of Clinical Trials. **2013**, 663-694

441 Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets. **2013**, 431-455

440 Tumor Immunotherapy by Utilizing a Double-Edged Sword, Chemokines. **2013**, 97-118

439 Molecular Oncology in Gynecologic Cancer. **2013**, 623-633 1

438 Principles of tumor immunology. **2013**, 925-934

437 Immunologic Interpretation of Cancer Biology: Impact on Clinical Outcome. **2013**, 83-104

436 Tregs. **2013**, 1-11

435 The Role of Tumor Associated Neutrophils in Cancer. **2013**, 457-478

434 Regulatory T Cells in Patients with Cancer. **2013**, 511-523

433 Role of Microenvironment in Regulating Stem Cell and Tumor Initiating Cancer Cell Behavior and Its Potential Therapeutic Implications. **2014**, 159-169

432 What Is the Future of Immunotherapy in Ovarian Cancer?. **2014**, 323-337

431 Role of Microenvironment in Regulating Stem Cell and Tumor Initiating Cancer Cell Behavior and Its Potential Therapeutic Implications. **2014**, 301-312

430 Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. **2014**, 187-214

429 Angiogenesis and Immune Suppression in Cancer. **2014**, 213-238

428 Regulatory T Cells and Cancer. **2014**, 1-36

427 Effects of Regulatory T Cell Dendritic Cell Interactions on Adaptive Immune Responses. **2014**, 21-27

426 S100A9, Inflammation, and Regulation of Immune Suppression in Cancer. **2014**, 295-310

425 In vitro Regulatory T cells Differentiation From Na⁺ve T Cells. **2014**, 4,

424 Dendritic Cell-Based Cancer Vaccines. **2014**, 69-87

423 Macrophages and Tumor Development. **2014**, 185-212

422 Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy. **2015**, 427-439

421 Tumor-Associated Macrophages and Cancer Development. **2015**, 375-382

420 Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers. **2015**, 203-215

419 Microenvironmental Control of Metastatic Progression. **2015**, 125-137

418 Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma. **2015**, 299-311

417 Quality of CTL Therapies: A Changing Landscape. **2015**, 303-349

- 416 Immunoregulatory Myeloid Cells in the Tumor Microenvironment. **2016**, 61-71
- 415 Combination of Hyperthermia and Immunotherapy: Hyperthermia and Na α e T-cell Therapy. **2016**, 341-353
- 414 Vaccines Against Lassa Fever. **2016**, 923-932
- 413 The Future in Ovarian Cancer: Advances in Immunotherapies. **2017**, 143-168
- 412 Melanoma Stem Cells. **2017**, 311-337
- 411 Introduction to Modern Immunology. **2017**, 1-22
- 410 Ovarian cancer and inflammation. Part 2. Anti-inflammatory cytokines. **2018**, 8, 206-209 1
- 409 Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies. **2019**, 181-192 1
- 408 Landscape of tumor-infiltrating immune cells in human immunogenic cancers: B cells are inversely associated with CD8T cells, but positively correlated with Treg cells.
- 407 Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. **2019**, 2, 23-35 1
- 406 Immune structures of the greater omentum and their role in cancer metastasis. **2019**, 100, 935-943 0
- 405 Sialic Acids and TAGs of Tumor Cells to Escape Immune Surveillance and Immune Editing. **2020**, 169-192
- 404 Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma. **2020**, 333-354
- 403 Prognostic Value of Innate and Adaptive Immunity in Cancers. **2020**, 403-415
- 402 The Roles of CD4+ T-Cells in Tumor Immunity. **2020**, 63-90
- 401 The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden.
- 400 HPK1 Influences Regulatory T Cell Functions. **2020**, 4, 382-391 3
- 399 Tumor Immunity Microenvironment-based classifications of bladder cancer for enhancing cancer immunotherapy.

398	A pH-responsive polymersome depleting regulatory T cells and blocking A2A receptor for cancer immunotherapy. 1	0
397	Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation. 2021 , 2021, 8321400	4
396	Alphavirus-Driven Interferon Gamma (IFN γ) Expression Inhibits Tumor Growth in Orthotopic 4T1 Breast Cancer Model. 2021 , 9,	0
395	Immune Evasion Mechanism and AXL. 2021 , 11, 756225	1
394	Regulatory T cells promote cancer immune-escape through integrin α ₈ -mediated TGF- β activation. 2021 , 12, 6228	6
393	Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma. 2021 , 8, 735585	0
392	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. 2021 , 12, 770390	6
391	Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer. 2020 , 205-233	
390	Tumour-directed microenvironment remodelling at a glance. 2020 , 133,	4
389	Immunology and Immunotherapy of Ovarian Cancer. 2020 , 487-540	
388	Liver Tumor Microenvironment. 2020 , 1296, 227-241	3
387	Improving responses to immunotherapy in head and neck squamous cell carcinoma. 2020 , 107-133	
386	Regulatory T-Cells and Th17 Cells in Tumor Microenvironment. 2020 , 91-106	1
385	The Immune Landscape in Women Cancers. 2020 , 180, 215-249	1
384	Immune Targets in Colorectal Cancer. 2020 , 205-230	
383	CHAPTER 10. Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities. 2020 , 259-306	
382	The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden.	
381	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. 2020 , 20, 1-16	1

- 380 Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
- 379 Macrophages in tumor: An inflammatory perspective. **2021**, 232, 108875 2
- 378 The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. **2021**, 6, eabf4034 2
- 377 Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia. **2021**, 1 1
- 376 CCR4 as a Therapeutic Target for Cancer Immunotherapy. **2021**, 13, 8
- 375 Regulatory T Cells in Cancer. **2008**, 41-67
- 374 Recombinant Viral and Bacterial Vaccines. **2007**, 217-250
- 373 Dendritic Cell Vaccines. **2007**, 251-274
- 372 Checkpoint Blockade and Combinatorial Immunotherapies. **2007**, 363-390
- 371 CD4+/CD25+ T-regulatory cells. **2008**, 65-72
- 370 Impact of Tumour Cell Death on the Activation of Anti-tumour Immune Response. **2009**, 347-370
- 369 Role of TGF- β in Tumor Progression and Metastasis. **2006**, 469-489
- 368 Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers. **2021**, 169-182
- 367 Tumor-Associated Macrophages and Cancer Development. **2021**, 365
- 366 Strategies to Target Tumor Immunosuppression. **2021**, 61-83
- 365 Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. **2020**, 04, 373-381
- 364 DNA vaccines for cervical cancer. **2010**, 2, 75-87 16
- 363 Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. **2009**, 10, 526-35 41

362	PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. 2010 , 2, 356-67	45
361	Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. 2007 , 7, 7	104
360	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. 2007 , 7, 12	94
359	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. 2009 , 9, 3	125
358	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. 2008 , 8, 16	68
357	Cancer vaccines: current directions and perspectives in prostate cancer. 2009 , 11, 31-6	5
356	Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. 2012 , 4, 376-89	219
355	Hematopoietic stem cells: interplay with immunity. 2012 , 2, 219-27	6
354	Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. 2013 , 13, 1	42
353	In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapy. 2013 , 5, 240-50	
352	Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF- κ B and NFAT signaling in tumor-associated T cells. 2013 , 13, 14	26
351	Increased B7-H1 and B7-H4 Expressions on Circulating Monocytes and Tumor-Associated Macrophages are Involved in Immune Evasion in Patients with Gastric Cancer. 2011 , 54, 1-10	18
350	Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. 2014 , 6, 129-39	68
349	The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma. 2013 , 5, 27-38	3
348	The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. 2014 , 7, 4272-81	9
347	Immunological parameters as a new lead in the diagnosis of ovarian cancer. 2015 , 7, 67-72	3
346	Radiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-545 in Lewis lung carcinoma cells. 2015 , 8, 2535-44	13
345	Interleukin-2 administration after modified radical mastectomy in breast cancer therapy increases peripheral regulatory T cells. 2015 , 8, 7816-22	6

344	Roles of Foxp3 in the occurrence and development of cervical cancer. 2015 , 8, 8717-30	21
343	High CD4+ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer. 2015 , 8, 11510-6	10
342	Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancer. 2015 , 7, 1699-711	28
341	The abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis. 2015 , 8, 15043-53	14
340	Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. 2015 , 5, 3276-85	25
339	Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway. 2015 , 8, 14608-18	14
338	Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. 2016 , 30, 59-66, 69	14
337	In Pursuit of Optimal Cyto-reduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon. 2009 , 59, 209-216	5
336	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. 2017 , 60, 119-125	5
335	[Evaluation of serum cytokines in small cell lung cancer and its clinical significance]. 2012 , 15, 11-6	1
334	Regulatory T Cells in Gynecologic Cancer. 2018 , 6, 34-42	11
333	The role of the immune system in brain metastasis. 2019 , 10, 33-48	18
332	Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy. 2019 , 7, 85-91	13
331	Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer. 2019 , 12, 3604-3612	14
330	Tumor cells induced-M2 macrophage favors accumulation of Treg in nasopharyngeal carcinoma. 2017 , 10, 8389-8401	9
329	Potential clinical value of interleukin-31 and interleukin-33 with their receptors expression as diagnostic and predictive factors in endometrial cancer: a case-control study. 2020 , 13, 1324-1332	1
328	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. 2020 , 10, 4585-4606	8
327	SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis. 2021 , 371, 104458	1

326	Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. 2021 , 108031	2
325	Cancer metabolism and tumor microenvironment: fostering each other?. 2021 , 1	3
324	Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer. 2021 , 12, 747780	1
323	Resolving the difference between left-sided and right-sided colorectal cancer by single-cell sequencing. 2021 ,	0
322	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. 2021 , 11, 766248	2
321	Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3CCR4CD8 T Cells That Mediate Rapid Hepatocyte Allograft Rejection. 2021 ,	0
320	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. 2021 ,	1
319	The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. 2021 , 13,	5
318	Idiopathic Myointimal Hyperplasia of Mesenteric Veins is a Peculiar Venous Ischemia that may be Diagnosed before Surgery. 2021 ,	2
317	A platform of patient-derived microtumors identifies treatment response and therapeutic vulnerabilities of ovarian cancer.	
316	Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity. 2021 , 11, 22966	0
315	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. 2021 , 13,	0
314	The Distribution of M2 Macrophage and Treg in Nasopharyngeal Carcinoma Tumor Tissue and the Correlation with TNM Status and Clinical Stage. 2021 , 22, 3447-3453	
313	Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.. 2021 , 12, 785050	1
312	Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer.. 2021 , 280, 121306	3
311	Immune System in Action.. 2021 , 1342, 1-43	
310	The Role of Reactive Oxygen Species on Cellular Fate and Function of Tumor-Infiltrating Lymphocytes. 2021 , 1-19	
309	Prognostic value of LINC02560 in colorectal cancer correlates with tumor microenvironment immunity.. 2021 , 12, 7507-7517	1

308	Multifaceted role of chemokines in solid tumors: From biology to therapy.. 2022,	5
307	Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.. 2022, 14,	3
306	Diet, lipids, and antitumor immunity.. 2022,	2
305	Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma.. 2022, 2022, 2607878	0
304	CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. 2022, 42, 101359	4
303	Improving therapeutic resistance: beginning with targeting the tumor microenvironment. 2021, 1-25	0
302	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.. 2022,	12
301	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.. 2021, 12, 808964	4
300	Pinpointing the tumor-specific T-cells via TCR clusters.	
299	Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.. 2022,	0
298	Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy.. 2022, 14,	9
297	The Role of Reactive Oxygen Species on Cellular Fate and Function of Tumor-Infiltrating Lymphocytes. 2022, 731-749	
296	Targeting FoxP3 gene to check out the impairment of tolerance in breast cancer patients. 2022, 34, 101864	0
295	CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.. 2022, 12, 1100	2
294	Immunometabolism in biofilm infection: lessons from cancer.. 2022, 28, 10	3
293	The next wave of cellular immunotherapies in pancreatic cancer.. 2022, 24, 561-576	4
292	The Radiobiology of TGF β 2022,	2
291	Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.. 2022,	3

290	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.. 2022 , 132,	4
289	Immunostimulation of tumor microenvironment by targeting tumor-associated macrophage with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy.. 2022 , 343, 78-78	0
288	Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition.. 2022 , 165, 91-101	1
287	Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy. 2022 , 43, 101400	2
286	Leveraging Macrophages for Cancer Theranostics.. 2022 , 114136	2
285	FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.. 2022 , 13, 740588	3
284	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.. 2021 , 10, 60	5
283	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.. 2022 , 113, 253-294	
282	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.. 2022 , 113, 1-57	0
281	Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful.. 2022 , 113, 107-140	0
280	Macrophages and their antitumor activity. 2022 , 165-183	
279	Glycans in Glycoimmunology. 2022 , 115-198	
278	Role of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting. 2022 , 193-215	
277	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.. 2022 ,	0
276	Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours.. 2022 , 14,	2
275	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma.. 2022 , 14,	0
274	A Neutrophil Extracellular Traps Signature Predicts the Clinical Outcomes and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.. 2022 , 9, 833771	2
273	Mitochondrial DNA on Tumor-Associated Macrophages Polarization and Immunity.. 2022 , 14,	0

272	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.. 2022 , 10, 830208	1
271	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.. 2022 , 23,	1
270	The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF- β receptor plus dual checkpoint inhibition maintains antitumor immune cells.. 2022 ,	0
269	Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity.. 2022 , 13, 812774	8
268	Do axis gut-breast microbiota orchestrate cancer progression?. 2022 ,	0
267	Interferon regulatory factor 3 upregulates the Treg recruitment factor CCL22 in response to double-stranded DNA in cancer cells.	
266	Polymeric Hydrogels for In Vitro 3D Ovarian Cancer Modeling.. 2022 , 23,	1
265	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients.. 2022 ,	0
264	Multiplexed single-cell analysis reveals prognostic and non-prognostic T cell types in human colorectal cancer.. 2022 ,	1
263	TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.. 2022 , 10,	1
262	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.. 2022 ,	7
261	circ_0004140 promotes LUAD tumor progression and immune resistance through circ_0004140/miR-1184/CCL22 axis.. 2022 , 8, 181	0
260	Dietary Lactobacillus-derived exopolysaccharide enhances immune checkpoint blockade therapy.. 2022 ,	5
259	Chemokines driven ovarian cancer progression, metastasis and chemoresistance: potential pharmacological targets for cancer therapy.. 2022 ,	1
258	Circulating Tregs accumulate in omental tumors and acquire adipose-resident features.. 2022 ,	0
257	Pinpointing the tumor-specific T-cells via TCR clusters.. 2022 , 11,	1
256	Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.. 2022 ,	1
255	Molecular linking of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and T-regulatory cells (FOXP3) and Th-17 (ROR γ) in advanced epithelial ovarian cancer. 2022 , 2, 62-68	

254	Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.. 2021 ,	2
253	Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. 2021 ,	
252	Identification of prognostic and therapeutic value of CC chemokines in Urothelial bladder cancer: evidence from comprehensive bioinformatic analysis. 2021 , 21, 173	0
251	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. 2021 , 13, eabf8495	1
250	Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer. 2021 ,	6
249	Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer.. 2021 , 2021, 4156187	2
248	Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.. 2021 , e14502	0
247	Depletion of central memory CD8 T cells might impede the antitumor therapeutic effect of Mogamulizumab.. 2021 , 12, 7280	0
246	Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer.. 2021 , 9, e0149721	1
245	Comprehensive analysis of prognostic value and immune infiltration of calpains in pancreatic cancer.. 2021 , 12, 2600-2621	0
244	The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma. 2021 , 21, 1306	0
243	Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.. 2021 , 11, 795547	5
242	Cell migration. 2022 , 67-82	
241	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.. 2022 , 3, e137	0
240	Pregnancy and Tumour: The Parallels and Differences in Regulatory T Cells.. 2022 , 13, 866937	1
239	A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.. 2022 ,	
238	The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression.. 2022 , 13, 850856	1
237	Endothelial Cells Activated by Extracellular Histones Promote Foxp3 Suppressive Treg Cells In Vitro.. 2022 , 23,	0

236 Innate Lymphoid Cells: Role in Immune Regulation and Cancer.. **2022**, 14,

235 Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.. **2022**, 150, 112949

1

234 Data_Sheet_1.PDF. **2020**,

233 Data_Sheet_2.PDF. **2020**,

232 Data_Sheet_3.PDF. **2020**,

231 Table_1.XLSX. **2020**,

230 Table_2.XLSX. **2020**,

229 Table_3.XLSX. **2020**,

228 Table_4.XLSX. **2020**,

227 Table_5.XLSX. **2020**,

226 Table_6.XLSX. **2020**,

225 Table_7.DOCX. **2020**,

224 Table_8.DOCX. **2020**,

223 Data_Sheet_1.PDF. **2019**,

222 Data_Sheet_1.PDF. **2020**,

221 Image_1.TIF. **2019**,

220 Image_2.TIF. **2019**,

219 Image_3.TIF. **2019**,

218 Table_1.DOCX. 2019,

217 Presentation_1.PPTX. 2020,

216 Data_Sheet_1.docx. 2019,

215 Image_1.TIF. 2019,

214 Image_2.TIF. 2019,

213 Image_3.TIF. 2019,

212 Image_4.tif. 2019,

211 Table_1.DOCX. 2019,

210 Table_2.DOCX. 2019,

209 Table_3.DOCX. 2019,

208 Table_4.DOCX. 2019,

207 Table_5.DOCX. 2019,

206 Table_6.DOCX. 2019,

205 Data_Sheet_1.DOCX. 2020,

204 Image_1.JPEG. 2019,

203 Table_1.XLSX. 2019,

202 Table_2.XLSX. 2019,

201 Table_3.XLSX. 2019,

200	Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures.. 2022,	1
199	Racial differences in the tumor immune landscape and survival of women with high-grade serous ovarian carcinoma.. 2022,	0
198	Association between effector-type regulatory T cells and immune checkpoint expression on CD8 T cells in malignant ascites from epithelial ovarian cancer.. 2022, 22, 437	0
197	Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model.. 2022, 14,	0
196	Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics. 2022, 301-339	
195	Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice.. 2022, 14,	0
194	Tumor-Associated Regulatory T Cells in Non-Small-Cell Lung Cancer: Current Advances and Future Perspectives.. 2022, 2022, 4355386	1
193	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.. 2022, 219,	2
192	The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.. 2022, 13, 886533	1
191	Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. 2022, 40, 45-74	3
190	CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.. 2022, 54, 637-648	0
189	New opportunities of immunocorrection in complex treatment of cervical cancer patients. 2021, 24, 115-122	
188	Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract.. 2022, 11,	
187	PD-L1 Mediates IFN γ Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma. 2022, 12,	1
186	Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies. 2022, 11, 1652	1
185	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. 2022,	3
184	The Regulatory-T-Cell Memory Phenotype: What We Know. 2022, 11, 1687	2
183	Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer. 2022, 2022, 1-16	

182	The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis. 2022 , 13,	0
181	Function and Therapeutic Intervention of Regulatory T Cells in Immune Regulation.	
180	Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach. 2022 , 13,	0
179	Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. 2022 , 156, 155916	0
178	TTYH3, a Potential Prognosis Biomarker Associated with Immune Infiltration and Immunotherapy Response in Lung Cancer.	
177	Ttyh3, a Potential Prognosis Biomarker Associated with Immune Infiltration and Immunotherapy Response in Lung Cancer.	
176	T cells in the peritoneum. 2022 ,	
175	Interplay between Solid Tumors and Tumor Microenvironment. 2022 , 13,	1
174	The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation. 2022 , 11, 1806	2
173	Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. 2022 , 10, e004605	0
172	Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components. 2022 , 23, 6215	0
171	Cluster of differentiation frequency on antigen presenting-cells: The next step to cervical cancer prognosis?. 2022 , 108, 108896	0
170	Impact of tumor microenvironment on adoptive T cell transfer activity. 2022 ,	0
169	CCL22-Polarized TAMs to M2a Macrophages in Cervical Cancer In Vitro Model. 2022 , 11, 2027	1
168	Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.	2
167	A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer. 2022 , 14, 2895	0
166	DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. 2022 , 24,	3
165	Identification of Paxillin as a Prognostic Factor for Glioblastoma via Integrated Bioinformatics Analysis. 2022 , 2022, 1-19	

- 164 Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. **2022**, 14, 3092 0
- 163 Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. **2022**, 329-344
- 162 Role of Lymphocytes in Cancer Immunity and Immune Evasion Mechanisms. **2022**, 159-182
- 161 Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments. **2022**, 245-266
- 160 Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. **2022**, 36, 514-532 2
- 159 Surgical Stress and Cancer Progression: New Findings and Future Perspectives. 0
- 158 Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma. 0
- 157 Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. **2022**, 45, 401-416 1
- 156 Immunoscore Combining CD8, FoxP3, and CD68-Positive Cells Density and Distribution Predicts the Prognosis of Head and Neck Cancer Patients. **2022**, 11, 2050 2
- 155 Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,
- 154 Role of tertiary lymphoid organs in the regulation of immune responses in the periphery. **2022**, 79, 0
- 153 Therapeutic targeting of regulatory T cells in cancer. **2022**, 2
- 152 The legacy of mRNA engineering: a line-up of pioneers for the Nobel Prize. **2022**, 0
- 151 Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. 13, 1
- 150 Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model. 1
- 149 Ovariakarzinom: Immuntherapie, quo vadis?.
- 148 TTYH3, a potential prognosis biomarker associated with immune infiltration and immunotherapy response in lung cancer. **2022**, 110, 108999
- 147 Colorectal cancer immunotherapy-Recent progress and future directions. **2022**, 545, 215816 1

146	Regulatory T-cell development in the tumor microenvironment.	4
145	Spatially targeting and regulating tumor-associated macrophages using a raspberry-like micellar system sensitizes pancreatic cancer chemoimmunotherapy.	0
144	CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells.	
143	Identification of the Binding Epitope of an Anti-mouse CCR4 Monoclonal Antibody, C4Mab-1. 2022 , 41, 214-220	0
142	Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer. 2022 , 14, 4037	1
141	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. 2022 , 15,	2
140	Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. 2022 ,	0
139	Belly Fat Weakens Immune Fitness. 2022 , 12, 1841-1843	0
138	A brief glimpse of a tangled web in a small world: Tumor microenvironment. 9,	0
137	Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews. 2022 , 14, 3834	1
136	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review. 2022 ,	0
135	Do autoimmune diseases influence the onset and progression of ovarian cancer? A systematic review and meta-analysis. ijgc-2022-003570	
134	Anti-CTLA-4 antibody might be effective against non-small cell lung cancer with large tumors.	0
133	Boosting doxil-based chemoimmunotherapy via reprogramming tumor-associated macrophages. 2023 , 451, 138971	1
132	Role of regulatory T cells in cancer. 2022 , 113-136	2
131	CXCR3 Expression in Regulatory T Cells Drives Interactions With Dendritic Cells in Tumors to Limit CD8 <sup>+</sup> T Cell Tumor Immunity.	0
130	CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment. 2022 , 11,	1
129	Identification of Tumor Microenvironment Scoring Scheme Based on Bioinformatics Analysis of Immune Cell Infiltration Pattern of Ovarian Cancer. 2022 , 2022, 1-10	0

128	Vascular Disruptive Hydrogel Platform for Enhanced Chemotherapy and Anti-Angiogenesis through Alleviation of Immune Surveillance. 2022 , 14, 1809	0
127	CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance. 2022 , 14, 4251	0
126	Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. 2022 , 8, e10450	0
125	The multifunctional nature of CD103 (Hv integrin) signaling in tissue-resident lymphocytes.	0
124	PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. 2022 , 610, 161-172	3
123	Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells.	1
122	Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment. 13,	1
121	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. 2022 , 14, 4344	0
120	Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.	2
119	Immune Tumor Microenvironment in Ovarian Cancer Ascites. 2022 , 23, 10692	1
118	Upregulation of EMID1 Accelerates to a Favorable Prognosis and Immune Infiltration in Lung Adenocarcinoma. 2022 , 2022, 1-15	0
117	Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian Cancer.	0
116	Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. 13,	1
115	IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts. 2022 , 10, e004585	0
114	High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis. 2022 , 22,	0
113	Cancer Immunotherapies Based on Genetically Engineered Macrophages. 2022 , 10, 1156-1166	0
112	Loss of the MLL3 tumor suppressor accelerates breast tumor onset via HIF1a-induced CCL2-mediated recruitment of CCR2+ regulatory T cells.	0
111	Isolation and Analysis of Tumor-Infiltrating Treg. 2023 , 51-63	0

110	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. 13,	0
109	ROS-Based Cancer Radiotherapy. 2022 , 265-309	0
108	The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. 2022 , 12, 1552	0
107	Friend and foe: the regulation network of ascites components in ovarian cancer progression.	0
106	Investigation on the regulatory T cells signature and relevant Foxp3/ STAT3 axis in esophageal cancer.	0
105	Immunometabolism in the tumor microenvironment and its related research progress. 12,	0
104	CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells. 13,	0
103	Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. 2022 ,	0
102	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. 2022 , 23, 13241	0
101	Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy. 2022 , 14, 5317	1
100	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. 2022 , 10, 2511	0
99	Metabolic guidance and stress in tumors modulate antigen-presenting cells. 2022 , 11,	0
98	A study on the correlation between M2 macrophages and regulatory T cells in the progression of colorectal cancer. 039361552211325	1
97	Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer. 12,	2
96	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. 2022 , 14, 5332	1
95	Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy. 13,	0
94	Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. 2022 , 479, 2219-2260	2
93	Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function. 2022 , 119,	1

92	Migratory Engineering of T Cells for Cancer Therapy. 2022 , 10, 1845	1
91	Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer. 13,	0
90	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. 13,	0
89	Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment. OF1-OF16	0
88	Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates. 2022 , 47, 101641	0
87	Immunotherapy in gynecologic malignancies. 2023 , 506-520.e7	0
86	Ovarian cancer stem cells: Critical roles in anti-tumor immunity. 13,	0
85	Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy. 13,	1
84	Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities. 2022 , 14, 5488	0
83	Immunology of Canine Melanoma.	0
82	Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. 13,	1
81	Identification and validation of novel biomarkers affecting bladder cancer immunotherapy via machine learning and its association with M2 macrophages. 13,	0
80	Polygenic Risk Scores Associated with Tumor Immune Infiltration in Common Cancers. 2022 , 14, 5571	0
79	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. 13,	0
78	Mitochondrial DNA Haplogroup M7 : A Predictor of Poor Prognosis for Colorectal Cancer Patients in Chinese Population.	0
77	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. 13,	0
76	Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer. 13,	0
75	Thermo-sensitive hydrogel-mediated locally sequential release of doxorubicin and palbociclib for chemo-immunotherapy of osteosarcoma. 2022 , 224, 111365	0

74	Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy. 2022 , 14, 5647	o
73	Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma. 34,	o
72	Emerging nano-strategies against tumour microenvironment (TME): a review. 2023 , 9, 100112	o
71	⌈ Lymphocytes as a Double-Edged SwordState of the Art in Gynecological Diseases. 2022 , 23, 14797	o
70	Propofol maintains Th17/Treg cell balance in elderly patients undergoing lung cancer surgery through GABAA receptor. 2022 , 23,	o
69	The Study of the Extracellular Matrix in Chronic Inflammation: A Way to Prevent Cancer Initiation?. 2022 , 14, 5903	1
68	A deubiquitination module essential for T reg fitness in the tumor microenvironment. 2022 , 8,	1
67	Downstream STING pathways IRF3 and NF- κ B differentially regulate CCL22 in response to cytosolic dsDNA.	o
66	Peptide antitumor vaccines targeting HER2/neu. 2022 , 21, 22-29	o
65	Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. 13,	o
64	CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy. 2022 , 23, 15638	o
63	Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions. 2023 , 40,	o
62	Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade. 2022 , 10, e005447	o
61	CCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma. 2022 , 50, 030006052211395	o
60	Systemic enhancement of antitumour immunity by peritumourally implanted immunomodulatory macroporous scaffolds.	o
59	The emerging roles of TLR and cGAS signaling in tumorigenesis and progression of ovarian cancer. 13,	o
58	Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy. 2206001	o
57	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. 2023 , 59, 23	o

- 56 Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma. ○
- 55 Time to Sleep: Immunologic Niche Switches Tumor Dormancy at Metastatic Sites. **2023**, 1-27 ○
- 54 Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. ○
- 53 Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. **2023**, 24, 974 ○
- 52 Clinical Significance of the Pre-Transplant CXCR3 and CCR6 Expression on T Cells In Kidney Graft Recipients. **2023**, ○
- 51 Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer. **2023**, 18, e0279590 ○
- 50 Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. **2023**, 158, 114180 ○
- 49 Macrophages as a Potential Immunotherapeutic Target in Solid Cancers. **2023**, 11, 55 3
- 48 Advancements in Cancer Immunotherapies. **2023**, 11, 59 ○
- 47 Rise of the natural red pigment prodigiosin as an immunomodulator in cancer. **2022**, 22, ○
- 46 Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses. **2023**, 15, 667 ○
- 45 Tumor-associated macrophages in prostate cancer: role in progression and therapy. **2023**, 153-180 ○
- 44 Understanding the squamous cell carcinoma immune microenvironment. 14, ○
- 43 Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients. **2023**, 2023, 1-17 ○
- 42 Circulating CD4+ Treg, CD8+ Treg, and CD3+ T Cell Subpopulations in Ovarian Cancer. **2023**, 59, 205 ○
- 41 CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy. ○
- 40 The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression. 14, ○
- 39 Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. ○

- 38 Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns. 14, ○
- 37 Propranolol reduces IFN- γ -driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer. **2023**, 110, 1-12 ○
- 36 Tregs are involved in VEGFA/ VASH1-related angiogenesis pathway in ovarian cancer. **2023**, 32, 101665 ○
- 35 Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses by *Mycobacterium indicus pranii*. 14, ○
- 34 Tregs constrain CD8+T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy. ○
- 33 Black phosphorus quantum dots conjugated with dual antibodies improve tumor infiltrating CD8 + T cell activation and cancer immunotherapy. ○
- 32 Regulatory cells and the effect of cancer immunotherapy. **2023**, 22, 1
- 31 Bacteria and macrophages in the tumor microenvironment. 14, ○
- 30 Chemical constituents, pharmacological effects, toxicology, processing and compatibility of Fuzi (lateral root of *Aconitum carmichaelii* Debx): A review. **2023**, 307, 116160 ○
- 29 Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer. **2023**, 28, 230-248 ○
- 28 CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling. **2023**, 23, ○
- 27 Increase of the T-reg-recruiting chemokine CCL22 expression in a progressive course of cervical dysplasia. ○
- 26 Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Prospectives: A Systematic Review. **2023**, 16, 313 ○
- 25 Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. **2023**, 15, 1282 ○
- 24 Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Publish Ahead of Print, ○
- 23 Advances in immune checkpoint inhibitors induced-cardiotoxicity. 14, ○
- 22 Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. **2023**, 11, e005968 1
- 21 Overexpression of Potential Markers of Regulatory and Exhausted CD8+ T Cells in the Peripheral Blood Mononuclear Cells of Patients with B-Acute Lymphoblastic Leukemia. **2023**, 24, 4526 ○

- 20 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 19 Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. 14, ○
- 18 Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma. 14, ○
- 17 Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. **2023**, 11, 614 ○
- 16 Chemokines and Chemokine Receptors in Cancer: An Update. **2023**, 1-30 ○
- 15 Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. **2023**, 41, 450-465 2
- 14 Role of T Helper 17 in Cancer Pathology: A Double-Edge Sword. **2023**, 1-24 ○
- 13 Immune determinants of the pre-metastatic niche. **2023**, 41, 546-572 ○
- 12 Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis. 14, ○
- 11 DNA hypomethylation mediates immune response in pan-cancer. **2023**, 18, ○
- 10 Anti-tumor effects of miR -34a by regulating immune cells in the tumor microenvironment. ○
- 9 Human fetal T cells: Insights into developmental specialization and mechanisms of lineage transition. ○
- 8 First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. **2023**, 42, ○
- 7 Tumor microenvironment signaling and therapeutics in cancer progression. ○
- 6 Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. **2023**, 59, ○
- 5 Apoptosis: aJanus bifronsin T-cell immunotherapy. **2023**, 11, e005967 ○
- 4 T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: First report from Upper Egypt. **2023**, 17, e0011258 ○
- 3 The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. 14, ○

- 2 Identification of hub genes and biological mechanisms underlying the pathogenesis of asthenozoospermia and chronic epididymitis. 14, ○
- 1 Late-stage MC38 tumours recapitulate features of human colorectal cancer [Implications for appropriate timepoint selection in preclinical studies. 14, ○